0001493152-18-011292.txt : 20180809 0001493152-18-011292.hdr.sgml : 20180809 20180809171448 ACCESSION NUMBER: 0001493152-18-011292 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180809 DATE AS OF CHANGE: 20180809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Interpace Diagnostics Group, Inc. CENTRAL INDEX KEY: 0001054102 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 222919486 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-24249 FILM NUMBER: 181006326 BUSINESS ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, STREET 2: BUILDING C, 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 412-224-6100 MAIL ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, STREET 2: BUILDING C, 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: PDI INC DATE OF NAME CHANGE: 20021113 FORMER COMPANY: FORMER CONFORMED NAME: PROFESSIONAL DETAILING INC DATE OF NAME CHANGE: 19980129 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________

Commission File Number: 000-24249

Interpace Diagnostics Group, Inc.

(Exact name of registrant as specified in its charter)

Delaware		22-2919486
(State or other jurisdiction of Incorporation or organization)		(I.R.S. Employer Identification No.)

Morris Corporate Center 1, Building C

300 Interpace Parkway, Parsippany, NJ 07054

(Address of principal executive offices and zip code)

(855) 776-6419

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [ ]	Accelerated filer [ ]	Non-accelerated filer [ ]	Smaller reporting company [X]
		(Do not check if a smaller reporting company)

Emerging Growth Company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

Class

Shares Outstanding

August 3, 2018

Common stock, $0.01 par value

28,194,275

INTERPACE DIAGNOSTICS GROUP, INC.

FORM 10-Q FOR PERIOD ENDED JUNE 30, 2018

TABLE OF CONTENTS

		Page No.
	PART I - FINANCIAL INFORMATION

Item 1.	Unaudited Interim Condensed Consolidated Financial Statements

	Condensed Consolidated Balance Sheets at June 30, 2018 (unaudited) and December 31, 2017	3

	Condensed Consolidated Statements of Operations for the three- and six-month periods ended June 30, 2018 and 2017 (unaudited)	4

	Condensed Consolidated Statement of Stockholders’ Equity for the six-month period ended June 30, 2018 (unaudited)	5

	Condensed Consolidated Statements of Cash Flows for the six-month periods ended June 30, 2018 and 2017 (unaudited)	6

	Notes to Unaudited Interim Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22

Item 4.	Controls and Procedures	34

	PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	35

Item 1A.	Risk Factors	35

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	35

Item 6.	Exhibits	35

Signatures		36

INTERPACE DIAGNOSTICS GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

	June 30, 2018			December 31, 2017
	(unaudited)

ASSETS
Current assets:
Cash and cash equivalents	$	10,084		$	15,199
Accounts receivable, net		7,647			3,437
Other current assets		1,474			1,172
Total current assets		19,205			19,808
Property and equipment, net		640			654
Other intangible assets, net		31,480			33,105
Other long-term assets		31			31
Total assets	$	51,356		$	53,598

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,173		$	391
Accrued salaries and bonus		938			1,394
Other accrued expenses		4,304			5,004
Current liabilities from discontinued operations		939			1,302
Total current liabilities		7,354			8,091
Contingent consideration		1,111			1,349
Other long-term liabilities		4,339			4,289
Total liabilities		12,804			13,729

Commitments and contingencies (Note 6)

Stockholders’ equity:
Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding		-			-
Common stock, $.01 par value; 100,000,000 shares authorized; 28,267,344 and 27,900,806 shares issued, respectively; 28,194,275 and 27,836,456 shares outstanding, respectively		282			278
Additional paid-in capital		174,360			173,062
Accumulated deficit		(134,410	)		(131,800	)
Treasury stock, at cost (73,069 and 64,350 shares, respectively)		(1,680	)		(1,671	)
Total stockholders’ equity		38,552			39,869
Total liabilities and stockholders’ equity	$	51,356		$	53,598

The accompanying notes are an integral part of these condensed consolidated financial statements.

INTERPACE DIAGNOSTICS GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited, in thousands, except for per share data)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2018			2017			2018			2017

Revenue, net	$	5,501		$	3,855		$	10,310		$	7,325
Cost of revenue (excluding amortization of $813 and $813 for the three months and $1,626 and $1,626 for the six months, respectively)		2,247			1,879			4,827			3,651
Gross profit		3,254			1,976			5,483			3,674
Operating expenses:
Sales and marketing		2,095			1,555			4,086			2,691
Research and development		518			413			1,019			719
General and administrative		1,726			2,793			3,897			4,315
Acquisition related amortization expense		813			813			1,626			1,626
Change in fair value of contingent consideration		-			-			-			(5,776	)
Total operating expenses		5,152			5,574			10,628			3,575

Operating (loss) income		(1,898	)		(3,598	)		(5,145	)		99
Interest expense		-			(216	)		-			(469	)
Loss on extinguishment of debt		-			(2,731	)		-			(4,278	)
Other income (expense), net		33			(8	)		144			(44	)
Loss from continuing operations before tax		(1,865	)		(6,553	)		(5,001	)		(4,692	)
Provision (benefit) for income taxes		8			(301	)		14			(298	)
Loss from continuing operations		(1,873	)		(6,252	)		(5,015	)		(4,394	)
(Loss) income from discontinued operations, net of tax		(44	)		(54	)		(95	)		502
Net loss	$	(1,917	)	$	(6,306	)	$	(5,110	)	$	(3,892	)

Basic (loss) income per share of common stock:
From continuing operations	$	(0.07	)	$	(0.65	)	$	(0.18	)	$	(0.64	)
From discontinued operations		(0.00	)		(0.01	)		(0.00	)		0.07
Net loss per basic share of common stock	$	(0.07	)	$	(0.65	)	$	(0.18	)	$	(0.57	)

Diluted (loss) income per share of common stock:
From continuing operations	$	(0.07	)	$	(0.65	)	$	(0.18	)	$	(0.64	)
From discontinued operations		(0.00	)		(0.01	)		(0.00	)		0.07
Net loss per diluted share of common stock	$	(0.07	)	$	(0.65	)	$	(0.18	)	$	(0.57	)
Weighted average number of common shares and common share equivalents outstanding:
Basic		27,933			9,657			27,894			6,877
Diluted		27,933			9,657			27,894			6,877

The accompanying notes are an integral part of these condensed consolidated financial statements.

INTERPACE DIAGNOSTICS GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited, in thousands)

	For The Six Months Ended
	June 30, 2018
	Shares		Amount
Common stock:
Balance at January 1		27,901	$	278
Common stock issued		366		4
Balance at June 30		28,267		282
Treasury stock:
Balance at January 1		64		(1,671	)
Treasury stock purchased		9		(9	)
Balance at June 30		73		(1,680	)
Additional paid-in capital:
Balance at January 1				173,062
Stock-based compensation expense				1,016
Common stock issued				282
Balance at June 30				174,360
Accumulated deficit:
Balance at January 1				(131,800	)
Net loss				(5,110	)
Adoption of ASC 606, see Note 3				2,500
Balance at June 30				(134,410	)
Total stockholders’ equity			$	38,552

The accompanying notes are an integral part of these condensed consolidated financial statements.

INTERPACE DIAGNOSTICS GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited, in thousands)

	Six Months Ended
	June 30,
	2018			2017

Cash Flows Used in Operating Activities
Net loss	$	(5,110	)	$	(3,892	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,710			1,937
Interest accretion		1			271
Provision for bad debt		-			25
Amortization of debt issuance costs		-			117
Mark to market on derivatives		-			61
Reversal of severance accrual		-			(2,034	)
Reversal of DOJ accrual		(350	)		-
Mark to market on warrants		(66	)		76
Loss on extinguishment of debt		-			4,278
Stock-based compensation, consulting agreements		24			-
Stock-based compensation		1,016			206
Change in fair value of contingent consideration		-			(5,776	)
Other changes in assets and liabilities:
Increase in accounts receivable		(1,710	)		(512	)
(Increase) decrease in other current assets		(40	)		53
Decrease in other long-term assets		-			220
Increase (decrease) in accounts payable		782			(1,358	)
Decrease in accrued salaries and bonus		(456	)		(1,549	)
Decrease in other accrued expenses		(944	)		(789	)
Increase in other long-term liabilities		116			94
Net cash used in operating activities		(5,027	)		(8,572	)

Cash Flows Used in Investing Activities
Purchase of property and equipment		(79	)		-
Net cash used in investing activities		(79	)		-

Cash Flows Used in Financing Activities
Issuance of common stock, net of expenses		-			22,263
Cash paid for repurchase of restricted shares		(9	)		(28	)
Net cash (used in) provided by financing activities		(9	)		22,235

Net (decrease) increase in cash and cash equivalents		(5,115	)		13,663
Cash and cash equivalents – beginning		15,199			602
Cash and cash equivalents – ending	$	10,084		$	14,265

The accompanying notes are an integral part of these condensed consolidated financial statements.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Tabular information in thousands, except per share amounts)

1.	BASIS OF PRESENTATION

The accompanying unaudited interim condensed consolidated financial statements and related notes (the “Interim Financial Statements”) should be read in conjunction with the consolidated financial statements of Interpace Diagnostics Group, Inc. (the “Company” or “Interpace”), and its wholly-owned subsidiaries, Interpace Diagnostics Lab Inc., Interpace Diagnostics Corporation and Interpace Diagnostics, LLC, and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the U.S. Securities and Exchange Commission (“SEC”) on March 23, 2018. The condensed Interim Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The condensed Interim Financial Statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements. Discontinued operations include the Company’s wholly owned subsidiaries: Group DCA, LLC, (“Group DCA”); InServe Support Solutions; and TVG, Inc. and its Commercial Services (“CSO”) business unit which was sold on December 22, 2015. All significant intercompany balances and transactions have been eliminated in consolidation. Operating results for the six-month period ended June 30, 2018 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2018.

2.	LIQUIDITY

As of June 30, 2018, the Company had cash and cash equivalents of $10.1 million, net accounts receivable of $7.6 million, total current assets of $19.2 million and total current liabilities of $7.4 million. For the six months ended June 30, 2018, the Company had a net loss of $5.1 million and cash used in operating activities was $5.0 million.

The Company does not expect to generate positive cash flows from operations for the year ending December 31, 2018. The Company believes however, that it has sufficient cash balances to meet near term obligations and further intends to meet its capital needs by revenue growth, containing costs, entering into strategic alliances as well as exploring other options, including the possibility of raising additional debt or equity capital as necessary. There is, however, no assurance the Company will be successful in meeting its capital requirements prior to becoming cash flow positive.

3.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially differ from those estimates.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

Revenue Recognition

Our Services

We are a fully integrated commercial and bioinformatics company that develops and provides clinically useful molecular diagnostic tests and pathology services. We develop and commercialize molecular diagnostic tests and related first line assays principally focused on early detection of patients at high risk of cancer and leverage the latest technology and personalized medicine for improved patient diagnosis and management. We currently have four commercialized molecular diagnostic assays in the marketplace for which we are receiving reimbursement: PancraGEN^®, which is a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using our proprietary PathFinderTG^®platform; ThyGenX^®(now known as ThyGeNEXT™), which is an oncogenic mutation panel that helps identify malignant thyroid nodules; ThyraMIR^®, which assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene expression assay; and RespriDX™, launched in September 2017, for assessing metastatic versus primary lung cancer tumors. RespriDX™ also utilizes our PathFinderTG^® platform and compares the genetic fingerprint of two or more sites of lung cancer to determine whether the neoplastic deposits are representative of a recurrence of cancer or a new primary (independent) cancer. We are also “soft launching” BarreGEN^®, an esophageal cancer risk classifier for Barrett’s Esophagus that also utilizes our PathFinder TG^®platform.

Adoption of Accounting Standards Codification Topic 606 (“ASC 606”), “Revenue from Contracts with Customers”

Effective January 1, 2018, the Company adopted ASC 606 which amends the guidance for the recognition of revenue from contracts with customers for the transfer of goods and services, by using the modified-retrospective method applied to any contracts that were not completed as of January 1, 2018. The results for the reporting period beginning after January 1, 2018, are presented in accordance with the new standard, although comparative information has not been restated and continues to be reported under the accounting standards and policies in effect for those periods.

Upon adoption, the Company performed a comprehensive analysis of existing revenue arrangements as of January 1, 2018 following the five-step model outlined in ASC 606. Based on our analysis, we recorded a cumulative adjustment to opening accumulated deficit and increase of accounts receivable of $2.5 million as of January 1, 2018. The cumulative impact was driven by a change in the timing of revenue recognition for certain payer categories and the related proprietary tests performed. The balance of accounts receivable related to the adjustment is approximately $0.9 million as of June 30, 2018.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

The following tables present the effect of the adoption of ASC Topic 606 on our condensed consolidated balance sheet and revenue as of and for the six months ended June 30, 2018:

Consolidated Balance Sheet:

	June 30, 2018
				(unaudited)
	As reported			Balances without Adoption of ASC 606			Effect of Change Higher/(Lower)
Accounts receivable, net	$	7,647		$	6,731		$	916
Accumulated deficit		(134,410	)		(136,910	)		(2,500	)

Revenue:

	For the six months ended June 30, 2018
			(unaudited)
	As reported		Balances without Adoption of ASC 606		Effect of Change Higher/(Lower)
Revenue, net	$	10,310	$	9,580	$	730

Historically, for certain third-party payers that did not have established contractual reimbursement rates or a predictable pattern of collectability, including commercial insurance carriers, Medicaid and certain direct-bill payers (primarily hospitals, but also laboratories), the Company previously recognized revenues when the fee was fixed or determinable and collectability was reasonably assured, which was upon request of third-party payer notification of payment or when cash was received. Under the new standard, the Company estimates the variable consideration within the transaction price for all third-party payers and proprietary tests and recognizes revenue as the Company satisfies its performance obligations.

In addition, the Company updated its estimates of the expected transaction price and related reimbursement rates for its payer categories and related proprietary tests based on the variable consideration guidance in ASC 606. This consisted of updating the reimbursement rates realized by the Company’s proprietary tests based on historical amounts received by each payer category for the corresponding tests performed.

Overall, other than an initial acceleration in the timing of our revenue recognition for certain payer categories, the adoption of this new standard will not have a significant impact on our reported total revenues and operating results as compared to amounts that would have been reported under the prior revenue recognition standard over our typical revenue cycle. Our accounting policies under the new standard were applied prospectively and are discussed further below.

Revenue Recognition after adoption of ASC 606

Upon adoption of ASC 606, the Company recognizes revenue when a customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

The Company derives its revenues from the performance of its proprietary tests. The Company’s performance obligation is fulfilled upon completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the proprietary tests performed. Revenue is recognized based on the estimated transaction price or net realizable value (“NRV”), which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. The Company regularly reviews the ultimate amounts received from the third-party payers and related estimated reimbursement rates and adjusts the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary from our estimates, we will adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known.

Disaggregated Revenues

We operate in a single operating segment and, therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting, which is consistent with internal management reporting. For the six-month periods ended June 30, 2018 and June 30, 2017, the majority of the Company’s revenues were derived from its molecular diagnostic tests.

Financing and Payment

Our payment terms vary by third-party payers and type of proprietary testing services performed. The term between invoicing and when payment is due is not significant.

Costs to Obtain or Fulfill a Customer Contract

Sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in sales and marketing expense in the condensed consolidated statements of operations.

Accounts Receivable

The Company’s accounts receivable represent unconditional rights to consideration and are generated using its proprietary tests. The Company’s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Prior to the adoption of ASC 606 on January 1, 2018, the Company recognized accounts receivable related to billings for Medicare, Medicare Advantage, and direct-bill payers on an accrual basis, net of contractual adjustment, when collectability was reasonably assured. Under ASC 606 accounts receivable is now recognized for all payer groups, net of contractual adjustment and net of estimated uncollectable amounts. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

Other Current Assets

Other current assets consisted of the following as of June 30, 2018 and December 31, 2017:

	June 30, 2018		December 31, 2017
	(unaudited)

Indemnification asset	$	875	$	875
Prepaid assets		556		266
Other		43		31
	$	1,474	$	1,172

Long-Lived Assets, including Finite-Lived Intangible Assets

Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to nine years in acquisition related amortization expense in the condensed consolidated statements of operations.

The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.

Discontinued Operations

The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations (“ASC 205-20”). ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note 11, Discontinued Operations for further information.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

Basic and Diluted Net Loss per Share

A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and six-month periods ended June 30, 2018 and 2017 is as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2018		2017		2018		2017
	(unaudited)

Basic weighted average number of common shares		27,933		9,657		27,894		6,877
Potential dilutive effect of stock-based awards		-		-		-		-
Diluted weighted average number of common shares		27,933		9,657		27,894		6,877

The following outstanding stock-based instruments were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2018		2017		2018		2017
	(unaudited)

Options		2,256		323		2,256		323
Stock-settled stock appreciation rights (SARs)		59		85		59		85
Restricted stock units (RSUs)		220		68		220		68
Warrants		13,542		17,105		13,542		17,105
		16,077		17,581		16,077		17,581

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

4.	OTHER INTANGIBLE ASSETS

The net carrying value of the identifiable intangible assets as of June 30, 2018 and December 31, 2017 are as follows:

			As of June 30, 2018			As of December 31, 2017
			(unaudited)
	Life		Carrying			Carrying
	(Years)		Amount			Amount
Diagnostic assets:
Asuragen acquisition:
Thyroid		9	$	8,519		$	8,519
RedPath acquisition:
Pancreas test		7		16,141			16,141
Barrett’s test		9		18,351			18,351
Total			$	43,011		$	43,011
Diagnostic lab:
CLIA Lab		2.3	$	609		$	609

Accumulated Amortization			$	(12,140	)	$	(10,515	)

Net Carrying Value			$	31,480		$	33,105

Amortization expense was approximately $0.8 million for the three-month periods ended June 30, 2018 and 2017, respectively, and approximately $1.6 million for the six-month periods ended June 30, 2018 and 2017, respectively. Amortization of our diagnostic assets begins upon launch of the product. Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:

2018				2019				2020				2021				2022
$	3,252			$	5,292			$	5,292			$	4,908			$	2,987

5.	FAIR VALUE MEASUREMENTS

Cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their relative short-term nature. The Company’s financial liabilities reflected at fair value in the condensed consolidated financial statements include contingent consideration and warrant liability. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including the market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:

	Level 1:	Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.

	Level 2:	Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.

	Level 3:	Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, are set forth in the tables below:

	As of June 30, 2018				Fair Value Measurements
	Carrying		Fair		As of June 30, 2018
	Amount		Value		Level 1		Level 2		Level 3
	(unaudited)
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	1,427	$	1,427	$	-	$	-	$	1,427
Other long-term liabilities:
Warrant liability ⁽²⁾		407		407		-		-		407
	$	1,834	$	1,834	$	-	$	-	$	1,834

	As of December 31, 2017				Fair Value Measurements
	Carrying		Fair		As of December 31, 2017
	Amount		Value		Level 1		Level 2		Level 3
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	1,581	$	1,581	$	-	$	-	$	1,581
Other long-term liabilities:
Warrant liability ⁽²⁾		473		473		-		-		473
	$	2,054	$	2,054	$	-	$	-	$	2,054

⁽¹⁾⁽²⁾See Note 7, Accrued Expenses and Long-Term Liabilities

In connection with the acquisition of certain assets from Asuragen, the Company recorded contingent consideration related to contingent payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement.

On June 21, 2017, the Company closed on a public offering issuing both Pre-Funded Warrants and Underwriters Warrants to purchase 2,600,000 shares and 575,000 shares of the Company’s common stock, respectively. Both the Pre-Funded and Underwriters Warrants include a cash settlement feature in the event of certain circumstances. Accordingly, both the Pre-Funded and Underwriters Warrants are classified as liabilities and were fair valued using the Black Scholes Option-Pricing Model, the inputs for which included exercise price of the respective warrants, market price of the underlying common shares, expected term, volatility based on the Company’s historical market price, and the risk-free rate corresponding to the expected term of the underlying agreement. Changes to the fair value of the warrant liabilities are recorded in Other income (expense), net. The Pre-Funded Warrants were fully exercised in 2017 and therefore the Company has no remaining liability associated with those warrants.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

A roll forward of the carrying value of the Contingent consideration liability and the Underwriters’ Warrant to June 30, 2018 is as follows:

								Cancellation		Mark to
	December 31,							of Obligation/		Market			June 30,
	2017		Payments			Accretion		Conversions		Adjustment			2018
	(unaudited)

Asuragen	$	1,581	$	(155	)	$	1	$	-	$	-		$	1,427

Underwriters Warrant		473		-					-		(66	)		407
	$	2,054	$	(155	)	$	1	$	-	$	(66	)	$	1,834

Certain of the Company’s non-financial assets, such as other intangible assets, are re-measured at fair value on a nonrecurring basis, if and when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

6.	COMMITMENTS AND CONTINGENCIES

Litigation

Due to the nature of the businesses in which the Company is engaged it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products.

The Company could also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.

As of June 30, 2018, the Company’s accrual for litigation and threatened litigation was not material to the condensed consolidated financial statements.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

RedPath – DOJ Settlement

In connection with the October 31, 2014 acquisition of RedPath Integrated Pathology, Inc., (“RedPath”), the Company assumed a liability for the settlement agreement entered into by the former owners of RedPath with the Department of Justice (“DOJ”). Under the terms of the settlement agreement, the Company was obligated to make payments to the DOJ for the calendar years ended December 31, 2014 through 2017, up to a maximum of $3.0 million. Payments were due on March 31st following the calendar year in which the revenue milestones were achieved. The Company made payments totaling $0.5 million during the year ended December 31, 2017 related to fiscal 2016 and had accrued $0.5 million for its potential liability for fiscal 2017, the final year of the settlement agreement. During the second quarter of 2018, the Company entered into an agreement with the DOJ to settle in full the outstanding fiscal 2017 liability at approximately $0.15 million and paid this amount as the final settlement payment in July 2018.

Prolias Technologies, Inc. v. PDI, Inc.

On April 8, 2015, Prolias Technologies, Inc. (“Prolias”) filed a complaint (the “Complaint”) against the Company with the Superior Court of New Jersey (Morris County) (the “Court”) in a matter entitled Prolias Technologies, Inc. v. PDI, Inc. In the Complaint, Prolias alleged that it and the Company entered into an August 19, 2013 collaboration agreement and an amendment thereto (collectively, the “Agreement”) whereby Prolias and the Company agreed to work in good faith to commercialize a diagnostic test known as “Thymira.” On March 9, 2017, the Court entered a final judgment in the Company’s favor against Prolias for the sum of $636,053 plus ten percent interest continuing to accrue on the principal balance of $500,000 unless and until paid. Final judgment was also entered in the Company’s favor and against Prolias, declaring Prolias is deemed to have executed and delivered to the Company a promissory note in the amount of $1,000,000 and Prolias is obligated to repay the Company the principal amount and all interest in accordance with the terms of the promissory note and the Agreement. On April 3, 2017, the final judgment against Prolias was recorded as a statewide lien. The Company has not recovered on the judgment against Prolias and no assurance can be given that the Company will ever be able to recover on the judgment in the future.

Pittsburgh Lease

On March 15, 2018, the Company amended the lease for its Pittsburgh laboratory to extend it through June 30, 2023. The lease is for 20,000 square feet of laboratory and office space, with monthly base rent of $33,333 beginning July 1, 2018, escalating by twenty-five percent (25%) on July 1, 2019 to $41,667 per month. The Company may, at its option, extend the term of the Lease for two consecutive terms of five years each, with the monthly base rent escalating by ten percent (10%) for each of the additional five year terms.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

7.	ACCRUED EXPENSES AND LONG-TERM LIABILITIES

Other accrued expenses consisted of the following as of June 30, 2018 and December 31, 2017:

	June 30, 2018		December 31, 2017
		(unaudited)

Accrued royalties	$	573	$	296
Indemnification liability		875		875
Contingent consideration		316		232
DOJ settlement		150		500
Accrued professional fees		690		700
Taxes payable		471		515
Unclaimed property		565		565
All others		664		1,321
	$	4,304	$	5,004

Long-term liabilities consisted of the following as of June 30, 2018 and December 31, 2017:

	June 30, 2018		December 31, 2017
	(unaudited)

Warrant liability	$	407	$	473
Uncertain tax positions		3,838		3,734
Other		94		82
	$	4,339	$	4,289

8.	STOCK-BASED COMPENSATION

Stock Incentive Plan

The Company’s stock-incentive program is a long-term retention program that is intended to attract, retain and provide incentives for talented employees, officers and directors, and to align stockholder and employee interests. Currently, the Company is able to grant options, SARs and restricted shares from the Interpace Diagnostics Group, Inc. Amended and Restated 2004 Stock Award and Incentive Plan, (the “Amended 2004 Plan”). Unless earlier terminated by action of its Board of Directors, the Amended 2004 Plan will remain in effect until such time as no stock remains available for delivery and the Company has no further rights or obligations under the Amended 2004 Plan with respect to outstanding awards thereunder.

Historically, stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for employees and members of the Board of Directors. Upon exercise, new shares will be issued by the Company. The Company granted stock options in 2017 which vest monthly over a one-year period. SARs are generally granted with a grant price equal to the market value of the common stock on the date of grant, vest one-third each year on the anniversary of the date of grant and expire five years from the date of grant. The restricted shares and restricted stock units granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and restricted stock units granted to board members generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

During March 2018, the Company’s Chief Executive Officer, Chief Financial Officer, senior executives and members of the Board were granted incentive stock options to purchase an aggregate of 745,600 shares of common stock with an exercise price of $1.01 per share and 186,400 RSUs, (subject generally to the executive’s or board member’s, as applicable, continued service with the Company), which vest one-third each year over a period of three years.

The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the six-month periods ended June 30, 2018 and 2017.

	Six Months Ended
	June 30, 2018			June 30, 2017
	(unaudited)

Risk-free interest rate		2.65	%		1.96	%
Expected life		6.00			4.91
Expected volatility		126.93	%		138.71	%
Dividend yield		-			-

The Company recognized approximately $0.4 million and $0.1 million of stock-based compensation expense during the three-month periods ended June 30, 2018 and 2017, respectively, and approximately $1.0 million and $0.2 million for the six month periods ended June 30, 2018 and 2017, respectively.

9.	INCOME TAXES

Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company’s valuation allowance position, it is the Company’s position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The following table summarizes income tax expense on (loss) income from continuing operations and the effective tax rate for the three- and six-month periods ended June 30, 2018 and 2017:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2018			2017			2018			2017
	(unaudited)						(unaudited)

Provision (benefit) from income tax	$	8		$	(301	)	$	14		$	(298	)
Effective income tax rate		(0.4	)%		4.6	%		(0.3	)%		6.4	%

Income tax expense for the three- and six-month periods ended June 30, 2018 was primarily due to minimum state and local taxes.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

10.

SEGMENT INFORMATION

Since December 22, 2015, the Company reports its operations as one segment, molecular diagnostics and bioinformatics. The Company’s reporting segment structure is reflective of the way both the Company’s management and chief operating decision maker view the business, make operating decisions and assess performance. This structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.

The Company’s molecular diagnostics and bioinformatics business focuses on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. Through the Company’s business, the Company aims to provide physicians and patients with diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal, endocrine and lung cancers, which are principally focused on early detection of patients at high risk of cancer. Customers in the Company’s segment consist primarily of physicians, hospitals and clinics. The service offerings throughout the segment have similar long-term average gross margins, contract terms, types of customers and regulatory environments. They are promoted through one centrally managed marketing group and the chief operating decision maker views their results on a combined basis.

11.

DISCONTINUED OPERATIONS

The components of liabilities classified as discontinued operations relate to Commercial Services and consist of the following as of June 30, 2018 and December 31, 2017:

	June 30, 2018		December 31, 2017
	(unaudited)

Accounts payable	$	192	$	192
Other		747		1,110
Current liabilities from discontinued operations		939		1,302
Total liabilities	$	939	$	1,302

12.

LONG-TERM DEBT

As more fully described in our Form 10-K filed on March 23, 2018, during the first six months of fiscal 2017 the Company entered into an Exchange Agreement related to its debt with an investor. The Company exchanged (the “RedPath Debt Exchange”) such then-existing debt for senior convertible notes (“Senior Convertible Notes”) of the Company on March 22, 2017. Subsequently between March 23, 2017 and April 18, 2017, the Senior Convertible Notes were converted into 3,795,429 shares of the Company’s common stock. The Company recorded a loss of $4.3 million in 2017 as a result of the exchange.

The Company has no long-term debt.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

13.

SUPPLEMENTAL CASH FLOW INFORMATION

The following table presents cash flows used in the Company’s discontinued operations for the six months ended June 30, 2018 and 2017:

	Six Months Ended
	June 30,
	2018			2017
	(unaudited)
Net cash used in operating activities of discontinued operations	$	(354	)	$	(883	)

Supplemental Cash Flow Information

(in thousands)

	Six Months Ended
	June 30,
	2018		2017
	(unaudited)
Operating
Adoption of ASC 606	$	2,500	$	-
Prepaid stock grants issued to vendors	$	286	$	-

Investing
Acquisition of property and equipment in other accrued expenses	$	46	$	-

Financing
Settlement of the RedPath Note	$	-	$	(8,098	)
Issuance of the Exchange Notes	$	-	$	11,375
Non-cash equity conversion costs	$	-	$	(173	)
Debt issuance costs	$	-	$	(511	)
Warrants issued through Termination Agreement*	$	-	$	193
Common shares issued in debt exchange	$	-	$	8,869

*See Note 14, Equity

14.

EQUITY

As more fully described in our Form 10-K filed on March 23, 2018, during the first quarter of fiscal 2017 the Company issued 2,793,000 common shares and 855,000 warrants for gross proceeds amounting to $12.2 million. In addition, as described in Note 12, Long-Term Debt, the Company issued 3,795,429 common shares in connection with the RedPath Debt Exchange and conversion of Senior Convertible Notes. As part of the Debt Exchange, the Company entered into a Termination Agreement with RedPath Equityholder Representative, LLC, terminating milestone and royalty payments and issued 5 year warrants to acquire an aggregate of 100,000 shares of the Company’s common stock at a fixed price of $4.69 per share.

During the second quarter of 2017, the Company completed a public offering of (i) 9,900,000 shares of the Company’s common stock (the “Firm Shares”), (ii) warrants to purchase 12,500,000 shares of Common Stock at an exercise price equal to $1.25 per share (the “Base Warrants”) and (iii) warrants to purchase 2,600,000 shares of Common Stock at an exercise price equal to $0.01 per share (the “Pre-Funded Warrants”). Each Firm Share and accompanying Base Warrant was sold for a combined effective price of $1.10, and each Pre-Funded Warrant and accompanying Base Warrant was sold for a combined effective price of $1.09. The issuance of the Firm Shares and the Pre-Funded Warrants resulted in combined gross proceeds of the offering totaling $13.7 million, with approximately $12.3 million of net funds available to the Company after deducting underwriting discounts and other stock issuance expenses.

INTERPACE DIAGNOSTICS GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Tabular information in thousands, except per share amounts)

15.

WARRANTS

There was no warrant activity for the six months ended June 30, 2018. Warrants outstanding for the period ended June 30, 2018 are as follows:

Description	Classification	Exercise Price		Expiration Date	Warrants Issued		Warrants Exercised			Warrants Cancelled/ Expired			Balance December 31, 2017		Balance June 30, 2018

Private Placement Warrants, issued January 25, 2017	Equity	$	4.69	June 2022		855,000		-			-			855,000		855,000
RedPath Warrants, issued March 22, 2017	Equity	$	4.69	September 2022		100,000		-			-			100,000		100,000
Pre-Funded Warrants, issued June 21, 2017	Liability	$	0.01	None		2,600,000		(2,600,000	)		-			-		-
Underwriters Warrants, issued June 21, 2017	Liability	$	1.32	December 2022		575,000		-			(40,000	)		535,000		535,000
Base & Overallotment Warrants, issued June 21, 2017	Equity	$	1.25	June 2022		14,375,000		(5,672,852	)		-			8,702,148		8,702,148
Vendor Warrants, issued August 6, 2017	Equity	$	1.25	August 2020		150,000		-			-			150,000		150,000
Warrants issued October 12, 2017	Equity	$	1.80	April 2022		3,200,000		-			-			3,200,000		3,200,000

						21,855,000		(8,272,852	)		(40,000	)		13,542,148		13,542,148

16.

RECENT ACCOUNTING PRONOUNCEMENTS

Recently adopted standards

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, “Revenue from Contracts with Customers,” previously defined in Note 3 as “ASC 606”. The standard, including subsequently issued amendments, replaces most existing revenue recognition guidance in U.S. GAAP. The key focus of the new standard is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this key focus, there is a five-step approach outlined in the standard. We adopted this new standard as of January 1, 2018, by using the modified-retrospective method. See Note 3, Summary of Significant Accounting Policies, for further details.

New standards not yet adopted

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which when effective will require organizations that lease assets (e.g., through “leases”) to recognize assets and liabilities for the rights and obligations created by the leases on the balance sheet. A lessee will be required to recognize assets and liabilities for leases with terms that exceed twelve months. The standard will also require disclosures to help investors and financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. The disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. The guidance is effective for annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial position and results of operations.

17.

SUBSEQUENT EVENTS

Nasdaq Correspondence

On May 4, 2018, the Company was notified by NASDAQ that we were no longer in compliance with the minimum bid price requirements of NASDAQ for continued listing and that we had until October 31, 2018 to regain compliance with this requirement or face delisting. On July 30, 2018 NASDAQ notified the Company that effective July 27, 2018 the Company was in compliance with the minimum bid price requirements of NASDAQ and the matter was determined to be closed.

Line of credit

Effective July 2018, the Company signed a letter of intent with Silicon Valley Bank to provide up to a 3-year $4,000,000 line of credit based on 80% of net available receivables, including a term portion of $850,000 to support capital expansions.

INTERPACE DIAGNOSTICS GROUP, INC.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q (“Form 10-Q”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Statements that are not historical facts, including statements about our plans, objectives, beliefs and expectations, are forward-looking statements. Forward-looking statements include statements preceded by, followed by or that include the words “believes,” “expects,” “anticipates,” “plans,” “estimates,” “intends,” “projects,” “should,” “could,” “may,” “will” or similar words and expressions. These forward-looking statements are contained throughout this Form 10-Q.

Forward-looking statements are only predictions and are not guarantees of future performance. These statements are based on current expectations and assumptions involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. These predictions are also affected by known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from those expressed or implied by any forward-looking statement. Many of these factors are beyond our ability to control or predict. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors. Such factors include, but are not limited to, the following:

	●	our ability to profitably grow our business, including our ability to finance our business on acceptable terms and successfully compete in the market;

	●	our ability to obtain broad adoption of and ability to grow or continue to secure sufficient levels of reimbursement for our molecular diagnostic tests in a changing reimbursement environment;

	●	whether we are able to successfully utilize our operating experience to sell our molecular diagnostic tests;

	●	our limited operating history as a molecular diagnostics company;

	●	our dependence on a concentrated selection of payers for our molecular diagnostic tests;

	●	the demand for our molecular diagnostic tests from physicians and patients;

	●	our reliance on our internal sales forces for business expansion;

	●	our dependence on third parties for the supply of some of the materials used in our molecular diagnostic tests;

	●	our ability to scale our operations, testing capacity and processing technology;

	●	our ability to compete successfully with companies with greater financial resources;

	●	our ability to obtain sufficient data and samples to cost effectively and timely perform sufficient clinical trials in order to support our current and future products;

	●	product liability claims against us;

	●	patent infringement claims against us;

	●	our involvement in current and future litigation against us or our ability to collect on judgements found in our favor;

INTERPACE DIAGNOSTICS GROUP, INC.

	●	the effect current and future laws, licensing requirements and regulation have on our business including the changing U.S. Food and Drug Administration, or the FDA, environment as it relates to molecular diagnosis;

	●	the effect of potential adverse findings resulting from regulatory audits of our billing practices and the impact such results could have on our business;

	●	our exposure to environmental liabilities as a result of our business;

	●	the susceptibility of our information systems to security breaches, loss of data and other disruptions;

	●	our ability to enter into effective electronic data interchange arrangements with our customers and third-party payers;

	●	our billing practices and our ability to collect on claims for the sale of our molecular diagnostic tests;

	●	our dependence on a third-party medical billing provider to operate effectively without delays, data loss, or other disruptions;

	●	our ability to attract and retain qualified sales representatives and other key employees and management personnel;

	●	competition in the segment of the molecular diagnostics industry in which we operate or expect to operate;

	●	our ability to obtain additional funding when necessary, in order to implement our business models and strategies;

	●	the results of any future impairment testing for other intangible assets;

	●	our ability to successfully identify, complete and integrate any future acquisitions and the effects of any such items on our revenues, profitability and ongoing business;

	●	our compliance with our license agreements and our ability to protect and defend our intellectual property rights;

	●	our ability to maintain our listing with The Nasdaq Capital Market (“NASDAQ”);

	●	the effect of adverse weather conditions, such as hurricanes and floods, on our business;

	●	failure of third-party service providers to perform their obligations to us;

	●	the volatility of our stock price and fluctuations in our quarterly and annual revenues and earnings;

	●	our ability to obtain and maintain sufficient laboratory space to meet our processing needs as well as our ability to pass regulatory inspections and continue to be certified CLIA laboratories and be CAP certified;

	●	our ability to commercially leverage our bioinformatics data with pharmaceutical and other potential partners in new revenue lines;

INTERPACE DIAGNOSTICS GROUP, INC.

	●	the ability to obtain or maintain supportive “guidelines” from trade and/or therapeutic related organizations focused on the clinical efficacy and utility of molecular diagnostics in our areas of focus; and

	●	determination that our Advanced Diagnostic Laboratory Tests (ADLTs) have become affected by the pricing provisions of the Processing Access to Medicare Act of 2014 (“PAMA”) which could result in an across the board reduction in our reimbursement rates; and

	●	Our ability to continue to develop and support our partially customized Laboratory Information System(LIMS), which is our automated basis of managing operations, storing data and customer information.

Please see Part I – Item 1A – “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017, filed March 23, 2018, as well as other documents we file with the U.S. Securities and Exchange Commission (“SEC”) from time-to-time, for other important factors that could cause our actual results to differ materially from our current expectations as expressed in the forward-looking statements discussed in this Form 10-Q. Because of these and other risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. In addition, these statements speak only as of the date of the report in which they are set forth and, except as may be required by law, we undertake no obligation to revise or update publicly any forward-looking statements for any reason.

INTERPACE DIAGNOSTICS GROUP, INC.

Company Overview

We are a fully integrated commercial and bioinformatics company that develops and provides clinically useful molecular diagnostic tests and pathology services. We develop and commercialize molecular diagnostic tests and related first line assays principally focused on early detection of patients at high risk of cancer and leverage the latest technology and personalized medicine for improved patient diagnosis and management. Our tests and services provide mutational analysis of genetic material contained in suspect cysts, nodules and lesions that helps physicians risk-stratify thyroid, pancreatic, and other cancers to better inform treatment decisions. The molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients. We currently have four commercialized molecular diagnostic assays in the marketplace for which we are receiving reimbursement: PancraGEN^®, which is a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using our proprietary PathFinderTG^®platform; ThyGenX^® (now ThyGeNEXT™) which is an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR^®, which assess thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene expression assay. We also launched in September 2017 RespriDX ™, which is a molecular test that helps physicians differentiate metastatic or recurrent lung cancer from the presence of a newly formed primary lung cancer. RespriDX™ also utilizes our PathFinderTG^® platform to compare the genomic fingerprint of two or more sites of lung cancer. We are also in the process of “soft launching” while we gather additional market data, BarreGen^®, an esophageal cancer risk classifier for Barrett’s Esophagus that also utilizes our PathFinderTG^® platform.

Our mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. Our laboratories are licensed pursuant to federal law under the Clinical Laboratory Improvement Amendments (“CLIA”) and are accredited by the College of American Pathologists (“CAP”) and New York State (“NYS”). We are leveraging our licensed and accredited laboratories to develop and commercialize our assays and products. We aim to provide physicians and patients with diagnostic options for detecting genomic and other molecular alterations that are associated with gastrointestinal, endocrine, and lung cancers. Our customers consist primarily of physicians, hospitals and clinics.

The global molecular diagnostics market is estimated to be $6.5 billion and is a segment within the approximately $60 billion in vitro diagnostics market according to statistics from Kalorama Information, publisher of the Worldwide Market for In Vitro Diagnostic Tests. We believe that the molecular diagnostics market offers significant growth and strong patient value given the substantial opportunity it affords to lower healthcare costs by helping to reduce unnecessary surgeries and ensuring the appropriate frequency of monitoring. We are keenly focused on growing our test volumes, securing additional coverage and reimbursement, maintaining and growing our current reimbursement, supporting revenue growth for our four commercialized innovative tests, introducing related first line product and service extensions, as well as expanding our business by developing and promoting synergistic products in our markets. We believe that BarreGen® is a potentially important pipeline product, also built on the PathFinderTG^®platform, which we believe is synergistic to our capabilities and potentially is a significant product opportunity in the gastrointestinal market, which is one of the sectors in which we operate.

Additional Reimbursement Coverage and Network Availability During 2018 (to-date)

Reimbursement progress is key for any molecular diagnostic company. We have been successful to date in 2018 expanding the reimbursement of our products. Specifically, the most significant progress we have made regarding payers to date in 2018 is as follows:

	●	In February 2018, we announced that Horizon Blue Cross Blue Shield of New Jersey, the oldest and largest health plan in New Jersey, covering 3.8 million patients living in the Northeastern United States, has agreed to cover ThyGenX^® (now ThyGeNEXT™) and ThyraMIR^®for its members effective January 9, 2018.

	●	In March 2018, we announced coverage of ThyGenX^®(now ThyGeNEXT™) and ThyraMIR^®by four new Blue Cross Blue Shield Plans: Blue Cross Blue Shield of Arizona, Blue Cross Blue Shield of South Carolina, Wellmark Blue Cross Blue Shield of Iowa, and Wellmark Blue Cross Blue Shield of South Dakota. These four plans combined represent over 5 million members.

INTERPACE DIAGNOSTICS GROUP, INC.

	●	In March 2018 we announced that we had entered into a laboratory services agreement with Acupath Laboratories, Inc. based in Plainview, New York (Long Island) whereby Acupath’s Commercial team will be selling ThyGenX^® (now ThyGeNEXT™) and ThyraMIR^® as part of its menu for endocrinologists, endocrine surgeons, and other physicians focused on the diagnosis and treatment of thyroid cancer.

	●	In April 2018, we announced that we had entered into an Agreement with BJC Healthcare of St. Louis, Missouri, one of the largest non-profit, integrated healthcare systems in the United States. The Agreement enables all physicians across the BJC system access to both ThyGenX^® (now ThyGeNEXT™) and ThyraMIR^® for patients with indeterminate thyroid nodules.

	●	In May 2018, we announced that we had entered into an agreement with Vanderbilt University Medical Center (VUMC) based in Nashville, TN, one of the largest academic medical centers in the country. The agreement enables all physicians across the Vanderbilt system access to both ThyGenX^® (now ThyGeNEXT™) and ThyraMIR^® for patients with indeterminate thyroid nodules.

	●	In May 2018, we announced that 14 Blue Cross Blue Shield plans across the country have published favorable coverage policies since the beginning of 2018 for ThyGenX® (now ThyGeNEXT™) and ThyraMIR^®, the Company’s molecular tests for indeterminate thyroid nodules. The list of plans includes many of the largest Blue Cross Blue Shield plans in the country, including Blue Shield of California and Horizon Blue Cross Blue Shield of New Jersey, previously announced by us. As a result of these 14 new policies, over 75 million members participating in these plans now have coverage for ThyGenX^® (now ThyGeNEXT™) and ThyraMIR^® testing.

	●	In June 2018, we announced coverage of ThyGenX^® (now ThyGeNEXT™) and ThyraMIR^® by Blue Cross Blue Shield of Florida, the largest health plan in Florida with over three million members. As of July 2018 there are twenty-seven regional Blue Cross Blue Shield regional payers, who have agreed to provide coverage for ThyGenX^® (now ThyGeNEXT™) and ThyraMIR^®.

	●	In July 2018, we announced that we expanded the application of PancraGEN^® beyond pancreatic cysts to include both biliary strictures and solid pancreatic lesions while gaining further Guideline support in the marketplace. PancraGEN^® is the first and only commercially available integrated molecular pathology test for pancreaticobiliary cancers.

	●	In July 2018, we also announced that CIGNA, one of the nation’s largest health plan providers, has agreed to cover ThyraMIR^®, the first microRNA gene expression classifier for thyroid nodules, as medically necessary. This is in addition to its coverage of ThyGenX^®, (now ThyGeNEXT™) as previously announced in 2017.

INTERPACE DIAGNOSTICS GROUP, INC.

DESCRIPTION OF REPORTING SEGMENTS

Since December 22, 2015, the Company reports its operations as one segment, molecular diagnostics and bioinformatics. The Company’s reporting segment structure is reflective of the way both the Company’s management and chief operating decision maker view the business, make operating decisions and assess performance. We believe this structure allows investors to better understand Company performance, better assess prospects for future cash flows, and make more informed decisions about the Company.

Revenue

The Company’s revenue is generated from the performance of its proprietary tests. The Company’s performance obligation is fulfilled upon completion, review and release of test results and subsequent billing to the third-party payer, hospital or service provider.

Revenue Recognition Prior to the Adoption of ASC 606

Historically, for the time periods through December 2017, the Company recognized revenue from services rendered when the following four revenue recognition criteria were met: persuasive evidence of an arrangement exists; services have been rendered; the selling price is fixed or determinable; and collectability is reasonably assured. The Company recognized revenue related to billings for Medicare, Medicare Advantage, and direct-bill payers on an accrual basis, net of contractual adjustment, when there was a predictable pattern of collectability. Contractual adjustments represent the difference between the list prices and the reimbursement rate set by Medicare and Medicare Advantage, or the amounts billed to direct-bill payers, which approximates the Medicare rate. For certain third-party payers that did not have established contractual reimbursement rates or a predictable pattern of collectability, including commercial insurance carriers and Medicaid, the Company believed that the fee was fixed or determinable and collectability was reasonably assured only upon request of third-party payer notification of payment or when cash is received, and recognized revenue at that time.

Until a contract had been negotiated with a commercial insurance carrier or governmental program, the services may or may not be covered by these entities’ existing reimbursement policies. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment, the related revenue was only recognized upon the earlier of payment notification or cash receipt. Accordingly, we recognized revenue from commercial insurance carriers, government programs, and certain direct-bill healthcare providers without contracts when payment was received.

Revenue Recognition after the Adoption of ASC 606

Beginning January 1, 2018 under ASC 606, the Company began to recognize revenue for billings less contractual allowances and estimated uncollectable amounts for all payer groups on the accrual basis based upon a thorough analysis of historical receipts. The net amount derived and used for revenue recognition is referred to as the “net realizable value” or (“NRV”) for the particular test and payer group from which reimbursement is received. This derived NRV will be evaluated quarterly or as needed and then applied to future periods until recalculated.

The Company completed its analysis of the ASC 606 impact and incorporated further analysis of first quarter 2018 collections from its commercial payer base in finalizing its ASC 606 adjustments. The impact of recording the cumulative catch-up adjustment under the modified retrospective method was $2.5 million, recorded as an increase to opening retained earnings on January 1, 2018. Prior periods have not been retrospectively adjusted. The Company also finalized its analysis of modified internal controls over financial reporting and the disclosures required starting with Form 10-Q for the first quarter of 2018.

INTERPACE DIAGNOSTICS GROUP, INC.

Cost of services

Cost of services consists primarily of the costs associated with operating our laboratories and other costs directly related to our tests. Personnel costs, which constitute the largest portion of cost of services, include all labor related costs, such as salaries, bonuses, fringe benefits and payroll taxes for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, and facility expenses.

CONDENSED CONSOLIDATED RESULTS OF OPERATIONS

The following table sets forth, for the periods indicated, certain statements of operations data. The trends illustrated in this table may not be indicative of future results.

Condensed Consolidated Results of Continuing Operations for the Quarter Ended June 30, 2018 Compared to the Quarter Ended June 30, 2017 (in thousands)

	Three Months Ended
	June 30,
	2018			2018			2017			2017

Revenue, net	$	5,501			100.0	%	$	3,855			100.0	%
Cost of revenue		2,247			40.8	%		1,879			48.7	%
Gross profit		3,254			59.2	%		1,976			51.3	%
Operating expenses:
Sales and marketing		2,095			38.1	%		1,555			40.3	%
Research and development		518			9.4	%		413			10.7	%
General and administrative		1,726			31.4	%		2,793			72.5	%
Acquisition related amortization expense		813			14.8	%		813			21.1	%
Total operating expenses		5,152			93.7	%		5,574			144.6	%

Operating loss		(1,898	)		-34.5	%		(3,598	)		-93.3	%
Interest expense		-			0.0	%		(216	)		-5.6	%
Loss on extinguishment of debt		-			0.0	%		(2,731	)		-70.8	%
Other income (expense), net		33			0.6	%		(8	)		-0.2	%
Loss from continuing operations before tax		(1,865	)		-33.9	%		(6,553	)		-170.0	%
Provision (benefit) for income tax		8			0.1	%		(301	)		-7.8	%
Loss from continuing operations		(1,873	)		-34.0	%		(6,252	)		-162.2	%
Loss from discontinued operations, net of tax		(44	)		-0.8	%		(54	)		-1.4	%
Net loss	$	(1,917	)		-34.8	%	$	(6,306	)		-163.6	%

INTERPACE DIAGNOSTICS GROUP, INC.

Revenue, net

Consolidated revenue for the three months ended June 30, 2018 increased by $1.6 million, or 42.7%, to $5.5 million, compared to $3.9 million for the three months ended June 30, 2017. This increase was principally attributable to increased test volume and commercial coverage for our thyroid tests and the change in revenue recognition under ASC 606 from cash basis to accrual of approximately $0.3 million for certain payer groups, as disclosed in the footnotes to the financial statements.

Cost of revenue

Consolidated cost of revenue for the three months ended June 30, 2018 increased by $0.4 million, or 19.6%. As a percentage of revenue cost of revenue decreased to 40.8% as compared to 48.7% in the comparable prior year period. The decrease as a percentage of revenue can be attributed to efficiencies in the manufacturing process relative to higher test volumes as well as the timing of purchases.

Gross profit

Consolidated gross profit for the three months ended June 30, 2018 increased $1.3 million, or 64.7%, to $3.3 million, compared to $2.0 million for the three months ended June 30, 2017. This increase was primarily related to the increase in revenue and improved laboratory cost efficiencies related to higher test volumes, as discussed above.

Sales and marketing expense

Sales and marketing expense was $2.1 million for the three months ended June 30, 2018 and as a percentage of revenue was 38.1%. For the three months ended June 30, 2017, sales and marketing expense was $1.6 million and 40.3% as a percentage of revenue. The increase in sales and marketing expense principally reflects an increase in salesforce costs as well as increased marketing spending.

Research and development

Research and development expense reflects clinical and research costs for supplies, laboratory tests and evaluations, scientific and administrative staff involved in clinical research, statistical research and product development related to new tests, products and programs. These costs were approximately $0.5 million for the three months ended June 30, 2018 and approximately $0.4 million for the three months ended June 30, 2017. As a percentage of revenue they were 9.4% for the three months ended June 30, 2018 and 10.7% for the three months ended June 30, 2017.

General and administrative

General and administrative expense for the three months ended June 30, 2018 was $1.7 million as compared to $2.8 million for the three months ended June 30, 2017. The decrease was primarily attributable to a net decrease in the Department of Justice (“DOJ”) accrual expense of approximately $0.5 million, $0.3 million in warrant issuance costs and $0.2 million in rent and moving expenses that occurred in the second quarter of 2017, with no similar cost in fiscal 2018.

INTERPACE DIAGNOSTICS GROUP, INC.

Acquisition related amortization expense

During both the three months ended June 30, 2018 and June 30, 2017, we recorded amortization expense of approximately $0.8 million in connection with the RedPath and Asuragen acquired intangible assets.

Operating loss

We experienced operating losses of $1.9 million for the three months ended June 30, 2018 and $3.6 million for the three months ended June 30, 2017. The decrease in the operating loss for the three months ended June 30, 2018 was primarily attributable to the increase in revenue and gross profit and the decrease in G&A expenses discussed above.

Provision (benefit) for income taxes

We had income tax expense of approximately $8,000 for the three months ended June 30, 2018 and an income tax benefit of approximately $0.3 million for the three months ended June 30, 2017. Income tax expense for 2018 was primarily due to required minimum state and local taxes. The income tax benefit for 2017 was primarily due to allocation of tax expense between continuing and discontinued operations.

Loss from discontinued operations, net of tax

We had a loss from discontinued operations of approximately $44,000 for the three months ended June 30, 2018 and a loss from discontinued operations of $0.1 million for the three months ended June 30, 2017. The loss from discontinued operations for both periods was primarily related to the allocation of income tax expense.

INTERPACE DIAGNOSTICS GROUP, INC.

Condensed Consolidated Results of Continuing Operations for the Six Months Ended June 30, 2018 Compared to the Six Months Ended June 30, 2017 (in thousands)

	Six Months Ended
	June 30,
	2018			2018			2017			2017

Revenue, net	$	10,310			100.0	%	$	7,325			100.0	%
Cost of revenue		4,827			46.8	%		3,651			49.8	%
Gross profit		5,483			53.2	%		3,674			50.2	%
Operating expenses:
Sales and marketing		4,086			39.6	%		2,691			36.7	%
Research and development		1,019			9.9	%		719			9.8	%
General and administrative		3,897			37.8	%		4,315			58.9	%
Acquisition related amortization expense		1,626			15.8	%		1,626			22.2	%
Change in fair value of contingent consideration		-			0.0	%		(5,776	)		-78.9	%
Total operating expenses		10,628			103.1	%		3,575			48.8	%

Operating (loss) income		(5,145	)		-49.9	%		99			1.4	%
Interest expense		-			0.0	%		(469	)		-6.4	%
Loss on extinguishment of debt		-			0.0	%		(4,278	)		-58.4	%
Other income (expense), net		144			1.4	%		(44	)		-0.6	%
Loss from continuing operations before tax		(5,001	)		-48.5	%		(4,692	)		-64.1	%
Provision (benefit) for income tax		14			0.1	%		(298	)		-4.1	%
Loss from continuing operations		(5,015	)		-48.6	%		(4,394	)		-60.0	%
(Loss) income from discontinued operations, net of tax		(95	)		-0.9	%		502			6.9	%
Net loss	$	(5,110	)		-49.6	%	$	(3,892	)		-53.1	%

Revenue, net

Consolidated revenue for the six months ended June 30, 2018 increased by $3.0 million, or 40.8%, to $10.3 million, compared to $7.3 million for the six months ended June 30, 2017.

This increase was principally attributable to increased test volume and commercial coverage for our thyroid tests and the change in revenue recognition under ASC 606 from cash basis to accrual of approximately $0.7 million for certain payer groups, as disclosed in the footnotes to the financial statements.

Cost of revenue

Consolidated cost of revenue for the six months ended June 30, 2018 increased by $1.2 million or 32.2% as compared to the same period in 2017. The primary reason for the increase was the increase in test volumes over the prior year. As a percentage of revenue, cost of revenue decreased to 46.8% as compared to 49.8% in the comparable prior year period due primarily to laboratory cost efficiencies relative to the increase in test volume and related revenues.

Gross profit

Gross profit, as a percentage of revenue, increased to 53.2% for the six months ended June 30, 2018 as compared to 50.2% for the six months ended June 30, 2017. This increase was also primarily due to laboratory cost efficiencies relative to the increase in test volume and related revenues.

INTERPACE DIAGNOSTICS GROUP, INC.

Sales and marketing expense

Sales and marketing expenses were $4.1 million for the six months ended June 30, 2018, and as a percentage of revenue was 39.6%. For the six months ended June 30, 2017, sales and marketing expenses were $2.7 million and 36.7% as a percentage of revenue. The increase in sales and marketing expense principally reflect an increase in salesforce costs as well as increased marketing spending.

Research and development

Research and development costs totaled $1.0 million for the six months ended June 30, 2018 and as a percentage of revenue were 9.9%. For the six months ended June 30, 2017 the expense was $0.7 million and as a percentage of revenue was 9.8%. The increase in research and development expenses was primarily due to an increase in certain costs that are internally allocated to Research and Development, as well as an increase in employee stock compensation costs affiliated with research and development personnel.

General and administrative

General and administrative expense for the six months ended June 30, 2018 was $3.9 million as compared to $4.3 million for the six months ended June 30, 2017. This decrease was primarily attributable to a comparable reduction in DOJ settlement expense totaling $1.1 million, partially offset by an increase in employee expenses of $0.6 million in the current year.

Acquisition related amortization expense

During both the six months ended June 30, 2018 and June 30, 2017, we recorded amortization expense of approximately $1.6 million.

Change in fair value of contingent consideration

During the six months ended June 30, 2017, there was a $5.8 million reduction in the contingent consideration liability as the result of the termination of the contingent consideration agreement with Redpath Equity Holders Representative, LLC, for amounts associated with future royalty payments for the assets acquired from Redpath, as disclosed in Note 14, Equity of the footnotes to the financial statements.

Operating (loss) income

We experienced an operating loss of $5.1 million for the six months ended June 30, 2018, and operating income of $0.1 million during the six months ended June 30, 2017. The operating income for the six months ended June 30, 2017 was primarily attributable to the reversal of our RedPath contingent consideration liability of $5.8 million. Without the reversal of contingent consideration, the operating income from continuing operations for the six months ended June 30, 2017 would have been an operating loss of $5.7 million.

INTERPACE DIAGNOSTICS GROUP, INC.

Provision (benefit) for income taxes

We had income tax expense of approximately $14,000 for the six months ended June 30, 2018 and an income tax benefit of approximately $0.3 million for the six months ended June 30, 2017. The income tax benefit for 2017 was primarily due to allocation of tax expense between continuing and discontinued operations.

(Loss) income from discontinued operations, net of tax

We had a loss from discontinued operations of $0.1 million for the six months ended June 30, 2018 and income from discontinued operations of $0.5 million for the six months ended June 30, 2017. The income from discontinued operations for the six months ended June 30, 2017 was primarily related to reversals of severance accruals.

LIQUIDITY AND CAPITAL RESOURCES

For the six months ended June 30, 2018, we had an operating loss of $5.1 million. As of June 30, 2018, we had cash and cash equivalents of $10.1 million, total current assets of $19.2 million and current liabilities of $7.4 million.

We intend to meet our capital needs by driving revenue growth, containing costs as well as exploring other options, including the possibility of raising additional debt or equity capital as necessary. There is, however, no guarantee that additional capital can be raised to fund our future operations.

During the six months ended June 30, 2018, net cash used in operating activities was $5.0 million, of which $4.6 million was used in continuing operations and $0.4 million was used in discontinued operations. The main component of cash used in operating activities during the six months ended June 30, 2018 was the net loss of $5.1 million. During the six months ended June 30, 2017, net cash used in operating activities was $8.6 million, of which $7.7 million was used in continuing operations and $0.9 million was used in discontinued operations. The main component of cash used in operating activities during the six months ended June 30, 2017 was a net loss of $3.9 million, a decrease in accrued payroll of $1.5 million and accounts payable of $1.4 million related to past due obligations from the prior year. For the six months ended June 30, 2018, there was $0.1 million of net cash used in investing activities for the purchase of lab and computer equipment. There was no cash used in investing activities for the six months ended June 30, 2017.

For the six months ended June 30, 2017, there was net cash provided from financing activities of $22.2 million, which resulted from the issuance of common stock in our four direct offerings completed in the first six months of 2017.

Inflation

We do not believe that inflation had a significant impact on our results of operations for the periods presented. On an ongoing basis, we attempt to minimize any effects of inflation on our operating results by controlling operating costs and whenever possible, seeking to insure that billing rates reflect increases in costs due to inflation.

Off-Balance Sheet Arrangements

None.

INTERPACE DIAGNOSTICS GROUP, INC.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act as of the end of the period covered by this Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives including that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In addition, management is required to apply its judgment in evaluating the benefits of possible disclosure controls and procedures relative to their costs to implement and maintain.

Based on the evaluation of the Company’s disclosure controls and procedures, as that term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended, the Chief Executive Officer of the Company and the Chief Financial Officer of the Company have concluded that the Company’s disclosure controls and procedures are effective as of June 30, 2018.

Reference should be made to our most recent Annual Report on Form 10-K for additional information regarding discussion of the effectiveness of the Company’s controls and procedures.

Changes in internal controls

There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

INTERPACE DIAGNOSTICS GROUP, INC.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

“Item 3- Legal Proceedings” of our most recent Annual Report on Form 10-K filed on March 23, 2018 includes a discussion of our legal proceedings, as does Note 6, Commitments and Contingencies, to the accompanying condensed consolidated financial statements. During the fiscal quarter ended June 30, 2018, there have been no material changes from the proceedings disclosed in our Form 10-K.

Item 1A. Risk Factors.

Not applicable as we are a smaller reporting company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On June 13th and 15th, 2018, the Company issued 325,000 shares of common stock in consideration of services to be rendered in respect of two consulting agreements it entered into during the quarter ended June 30, 2018. The issuances were exempt from registration pursuant to the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

None.

Item 6. Exhibits

Exhibit No.		Description

31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

32.1+		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith.

32.2+		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith.

101		The following financial information from this Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2018 formatted in XBRL (Extensible Business Reporting Language) and furnished electronically herewith: (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statement of Stockholders’ Equity; (iv) the Condensed Consolidated Statements of Cash Flows; and (v) the Notes to Condensed Consolidated Financial Statements.

	+	Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference to any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 9, 2018		Interpace Diagnostics Group, Inc.
		(Registrant)

		/s/ Jack E. Stover
		Jack E. Stover
		President and Chief Executive Officer
		(Principal Executive Officer)

		/s/ James Early
		James Early
		Chief Financial Officer
		(Principal Financial Officer)

		/s/ Thomas Freeburg
		Thomas Freeburg
		Chief Accounting Officer
		(Principal Accounting Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Jack E. Stover, certify that:

	1.	I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 of Interpace Diagnostics Group, Inc. (the “registrant”);

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	August 9, 2018	/s/ Jack E. Stover
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, James Early, certify that:

	1.	I have reviewed this Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 of Interpace Diagnostics Group, Inc. (the “registrant”);

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	August 9, 2018	/s/ James Early
		Chief Financial Officer
		(Principal Financial Officer)

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Interpace Diagnostics Group, Inc. (the “Company”) on form 10-Q for the period ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jack E. Stover, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	August 9, 2018	/s/ Jack E. Stover
		Chief Executive Officer
		(Principal Executive Officer)

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Interpace Diagnostics Group, Inc. (the “Company”) on form 10-Q for the period ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James Early, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	August 9, 2018	/s/ James Early
		Chief Financial Officer
		(Principal Financial Officer)

EX-101.INS 6 idxg-20180630.xml XBRL INSTANCE FILE 0001054102 2018-01-01 2018-06-30 0001054102 2017-12-31 0001054102 2018-06-30 0001054102 2017-01-01 2017-06-30 0001054102 IDXG:DiagnosticAssetsThyroidMember IDXG:AsuragenAcquisitionMember 2018-01-01 2018-06-30 0001054102 IDXG:DiagnosticAssetsPancreasTestMember IDXG:RedPathAcquisitionMember 2018-01-01 2018-06-30 0001054102 IDXG:DiagnosticAssetsBarrettsTestMember IDXG:RedPathAcquisitionMember 2018-01-01 2018-06-30 0001054102 IDXG:DiagnosticLabCLIALabMember 2018-01-01 2018-06-30 0001054102 IDXG:DiagnosticAssetsThyroidMember IDXG:AsuragenAcquisitionMember 2017-12-31 0001054102 IDXG:DiagnosticAssetsThyroidMember IDXG:AsuragenAcquisitionMember 2018-06-30 0001054102 IDXG:DiagnosticAssetsPancreasTestMember IDXG:RedPathAcquisitionMember 2017-12-31 0001054102 IDXG:DiagnosticAssetsPancreasTestMember IDXG:RedPathAcquisitionMember 2018-06-30 0001054102 IDXG:DiagnosticAssetsBarrettsTestMember IDXG:RedPathAcquisitionMember 2018-06-30 0001054102 IDXG:DiagnosticAssetsBarrettsTestMember IDXG:RedPathAcquisitionMember 2016-12-31 0001054102 IDXG:DiagnosticAssetsMember 2017-12-31 0001054102 IDXG:DiagnosticLabCLIALabMember 2017-12-31 0001054102 IDXG:DiagnosticLabCLIALabMember 2018-06-30 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2017-12-31 0001054102 2015-12-21 2015-12-22 0001054102 IDXG:CompanysCounterClaimAgainstProliasMember 2017-03-08 2017-03-09 0001054102 us-gaap:CommonStockMember 2017-12-31 0001054102 us-gaap:TreasuryStockMember 2017-12-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001054102 us-gaap:RetainedEarningsMember 2017-12-31 0001054102 IDXG:RedPathWarrantsMember 2018-06-30 0001054102 IDXG:PrefundedWarrantsMember 2017-06-21 0001054102 IDXG:UnderwriterWarrantMember 2017-06-21 0001054102 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0001054102 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001054102 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001054102 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember IDXG:AsuragenMember 2017-12-31 0001054102 us-gaap:FairValueInputsLevel1Member IDXG:AsuragenMember 2017-12-31 0001054102 us-gaap:FairValueInputsLevel2Member IDXG:AsuragenMember 2017-12-31 0001054102 us-gaap:FairValueInputsLevel3Member IDXG:AsuragenMember 2017-12-31 0001054102 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-06-30 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2018-06-30 0001054102 us-gaap:FairValueInputsLevel1Member 2018-06-30 0001054102 us-gaap:FairValueInputsLevel2Member 2018-06-30 0001054102 us-gaap:FairValueInputsLevel3Member 2018-06-30 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember IDXG:AsuragenMember 2018-06-30 0001054102 us-gaap:FairValueInputsLevel1Member IDXG:AsuragenMember 2018-06-30 0001054102 us-gaap:FairValueInputsLevel2Member IDXG:AsuragenMember 2018-06-30 0001054102 us-gaap:FairValueInputsLevel3Member IDXG:AsuragenMember 2018-06-30 0001054102 IDXG:AsuragenMember 2017-12-31 0001054102 IDXG:PrefundedWarrantsMember 2018-01-01 2018-06-30 0001054102 IDXG:PrefundedWarrantsMember 2018-06-30 0001054102 IDXG:UnderwriterWarrantsMember 2017-12-31 0001054102 IDXG:PrivatePlacementWarrantsMember 2018-01-01 2018-06-30 0001054102 IDXG:PrivatePlacementWarrantsMember 2018-06-30 0001054102 IDXG:RedPathWarrantsMember 2018-01-01 2018-06-30 0001054102 IDXG:BaseandOverallotmentWarrantsMember 2018-01-01 2018-06-30 0001054102 IDXG:BaseandOverallotmentWarrantsMember 2018-06-30 0001054102 IDXG:VendorWarrantsMember 2018-01-01 2018-06-30 0001054102 IDXG:VendorWarrantsMember 2018-06-30 0001054102 IDXG:WarrantsIssuedMember 2018-01-01 2018-06-30 0001054102 IDXG:WarrantsIssuedMember 2018-06-30 0001054102 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001054102 us-gaap:CommonStockMember 2018-06-30 0001054102 us-gaap:TreasuryStockMember 2018-01-01 2018-06-30 0001054102 us-gaap:TreasuryStockMember 2018-06-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0001054102 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001054102 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001054102 us-gaap:RetainedEarningsMember 2018-06-30 0001054102 2017-03-31 0001054102 2016-12-31 0001054102 srt:MinimumMember 2018-01-01 2018-06-30 0001054102 srt:MaximumMember 2018-01-01 2018-06-30 0001054102 IDXG:AdoptionofASCTopicSixhundredSixMember 2018-01-01 2018-06-30 0001054102 IDXG:BalancesWithoutAdoptionofASCSixhundredSixMember 2018-06-30 0001054102 IDXG:BalancesWithoutAdoptionofASCSixhundredSixMember 2018-01-01 2018-06-30 0001054102 IDXG:EffectofChangeHigherLowerMember 2018-06-30 0001054102 IDXG:EffectofChangeHigherLowerMember 2018-01-01 2018-06-30 0001054102 IDXG:OptionsMember 2017-01-01 2017-06-30 0001054102 IDXG:StockSettledStockAppreciationRightsSARsMember 2017-01-01 2017-06-30 0001054102 IDXG:RestrictedStockUnitsRSUsMember 2017-01-01 2017-06-30 0001054102 IDXG:OptionsMember 2018-01-01 2018-06-30 0001054102 IDXG:StockSettledStockAppreciationRightsSARsMember 2018-01-01 2018-06-30 0001054102 IDXG:RestrictedStockUnitsRSUsMember 2018-01-01 2018-06-30 0001054102 IDXG:WarrantsMember 2018-01-01 2018-06-30 0001054102 IDXG:WarrantsMember 2017-01-01 2017-06-30 0001054102 IDXG:DiagnosticAssetsMember 2018-06-30 0001054102 IDXG:AsuragenMember 2018-01-01 2018-06-30 0001054102 IDXG:UnderwriterWarrantsMember 2018-01-01 2018-06-30 0001054102 IDXG:AsuragenMember 2018-06-30 0001054102 IDXG:UnderwriterWarrantsMember 2018-06-30 0001054102 IDXG:SettlementAgreementMember IDXG:RedPathMember 2017-01-01 2017-12-31 0001054102 IDXG:PittsburghLeaseMember 2018-03-14 2018-03-15 0001054102 IDXG:PittsburghLeaseMember IDXG:JulyOneTwoThousandEighteenMember 2018-03-14 2018-03-15 0001054102 IDXG:PittsburghLeaseMember IDXG:JulyOneTwoThousandNintyMember 2018-03-14 2018-03-15 0001054102 IDXG:StockIncentivePlanMember 2018-01-01 2018-06-30 0001054102 IDXG:ExchangeAgreementMember IDXG:SeniorConvertibleNotesMember IDXG:MarchTwentyThreeTwoThousandSeventeenaandAprilEighteenTwoThousandSeventeenMember 2018-01-01 2018-06-30 0001054102 IDXG:PrivatePlacementWarrantsMember 2017-12-31 0001054102 IDXG:RedPathWarrantsMember 2017-12-31 0001054102 IDXG:PrefundedWarrantsMember 2017-12-31 0001054102 IDXG:BaseandOverallotmentWarrantsMember 2017-12-31 0001054102 IDXG:VendorWarrantsMember 2017-12-31 0001054102 IDXG:WarrantsIssuedMember 2017-12-31 0001054102 IDXG:AdoptionofASCTopicSixhundredSixMember 2018-06-30 0001054102 2018-08-03 0001054102 2018-04-01 2018-06-30 0001054102 2017-04-01 2017-06-30 0001054102 2017-06-30 0001054102 IDXG:OptionsMember 2018-04-01 2018-06-30 0001054102 IDXG:StockSettledStockAppreciationRightsSARsMember 2018-04-01 2018-06-30 0001054102 IDXG:RestrictedStockUnitsRSUsMember 2018-04-01 2018-06-30 0001054102 IDXG:WarrantsMember 2018-04-01 2018-06-30 0001054102 IDXG:OptionsMember 2017-04-01 2017-06-30 0001054102 IDXG:StockSettledStockAppreciationRightsSARsMember 2017-04-01 2017-06-30 0001054102 IDXG:RestrictedStockUnitsRSUsMember 2017-04-01 2017-06-30 0001054102 IDXG:WarrantsMember 2017-04-01 2017-06-30 0001054102 IDXG:SettlementAgreementMember IDXG:RedPathMember srt:MaximumMember 2014-12-31 2017-12-31 0001054102 IDXG:SettlementAgreementMember IDXG:RedPathMember 2018-01-01 2018-06-30 0001054102 IDXG:StockIncentivePlanMember 2018-01-01 2018-03-31 0001054102 IDXG:StockIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-03-31 0001054102 2017-01-01 2017-03-31 0001054102 IDXG:RedPathDebtExchangeandConversionofSeniorConvertibleNotesMember 2017-01-01 2017-03-31 0001054102 IDXG:TerminationAgreementMember IDXG:RedPathEquityholderRepresentativeLLCMember 2017-03-31 0001054102 IDXG:TerminationAgreementMember IDXG:RedPathEquityholderRepresentativeLLCMember 2017-01-01 2017-03-31 0001054102 IDXG:BaseWarrantsMember 2017-06-30 0001054102 IDXG:PrefundedWarrantsMember 2017-06-30 0001054102 us-gaap:SubsequentEventMember 2018-07-01 2018-07-31 0001054102 us-gaap:SubsequentEventMember 2018-07-31 0001054102 IDXG:ExchangeAgreementMember IDXG:SeniorConvertibleNotesMember IDXG:MarchTwentyThreeTwoThousandSeventeenaandAprilEighteenTwoThousandSeventeenMember 2017-01-01 2017-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure IDXG:Integer utr:sqft Interpace Diagnostics Group, Inc. 0001054102 10-Q 2018-06-30 false --12-31 Smaller Reporting Company Q2

1302000

939000

.01

0.01

100000000

27900806

28267344

27836456

28194275

64350

73069

3897000

4315000

1726000

2793000

469000

216000

-5110000

-3892000

-5110000

-1917000

-6306000

39869000

38552000

278000

-1671000

173062000

-131800000

282000

-1680000

174360000

-134410000

-4278000

-2731000

4300000

22263000

9900000

366000

2793000

3795429

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; font: 11pt/107% Calibri, Helvetica, Sans-Serif">5.</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif">FAIR VALUE MEASUREMENTS</td></tr> </table>   Cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their relative short-term nature. The Company’s financial liabilities reflected at fair value in the condensed consolidated financial statements include contingent consideration and warrant liability. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including the market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; line-height: 107%"> </td> <td style="width: 48px; text-align: justify; line-height: 107%">Level 1:</td> <td style="text-align: justify; line-height: 107%">Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">Level 2:</td> <td style="text-align: justify; line-height: 107%">Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">Level 3:</td> <td style="text-align: justify; line-height: 107%">Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.</td></tr> </table>   In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, are set forth in the tables below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As of June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="text-align: center; line-height: 107%">Fair Value Measurements</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Carrying</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Fair</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As of June 30, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 1</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 2</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 3</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="18" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Liabilities:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Contingent consideration:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 30%; padding-left: 10pt; line-height: 107%">Asuragen (1)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">1,427</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">1,427</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">1,427</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Other long-term liabilities:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Warrant liability (2)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">407</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">407</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">407</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,834</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,834</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,834</td> <td style="line-height: 107%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As of December 31, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="text-align: center; line-height: 107%">Fair Value Measurements</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Carrying</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Fair</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As of December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 1</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 2</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 3</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Liabilities:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Contingent consideration:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 30%; padding-left: 10pt; line-height: 107%">Asuragen (1)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">1,581</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">1,581</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">1,581</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Other long-term liabilities:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Warrant liability (2)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">473</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">473</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">473</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,054</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,054</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,054</td> <td style="line-height: 107%"> </td></tr> </table>   (1)(2) See Note 7, Accrued Expenses and Long-Term Liabilities   In connection with the acquisition of certain assets from Asuragen, the Company recorded contingent consideration related to contingent payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement.   On June 21, 2017, the Company closed on a public offering issuing both Pre-Funded Warrants and Underwriters Warrants to purchase 2,600,000 shares and 575,000 shares of the Company’s common stock, respectively. Both the Pre-Funded and Underwriters Warrants include a cash settlement feature in the event of certain circumstances. Accordingly, both the Pre-Funded and Underwriters Warrants are classified as liabilities and were fair valued using the Black Scholes Option-Pricing Model, the inputs for which included exercise price of the respective warrants, market price of the underlying common shares, expected term, volatility based on the Company’s historical market price, and the risk-free rate corresponding to the expected term of the underlying agreement. Changes to the fair value of the warrant liabilities are recorded in Other income (expense), net. The Pre-Funded Warrants were fully exercised in 2017 and therefore the Company has no remaining liability associated with those warrants.   A roll forward of the carrying value of the Contingent consideration liability and the Underwriters’ Warrant to June 30, 2018 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Cancellation</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Mark to</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">December 31,</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">of Obligation/</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Market</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">June 30,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Payments</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Accretion</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Conversions</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Adjustment</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="22" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 32%; line-height: 107%">Asuragen</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 16%; text-align: right; line-height: 107%">1,581</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 6%; text-align: right; line-height: 107%">(155</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 5%; text-align: right; line-height: 107%">1</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 5%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 5%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">1,427</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Underwriters Warrant</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">473</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(66</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">407</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,054</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(155</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(66</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,834</td> <td style="line-height: 107%"> </td></tr> </table>   Certain of the Company’s non-financial assets, such as other intangible assets, are re-measured at fair value on a nonrecurring basis, if and when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 48px; font: 11pt/107% Calibri, Helvetica, Sans-Serif">13.</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif">SUPPLEMENTAL CASH FLOW INFORMATION</td></tr> </table>   The following table presents cash flows used in the Company’s discontinued operations for the six months ended June 30, 2018 and 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">Six Months Ended</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 107%">Net cash used in operating activities of discontinued operations</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">(354</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">(883</td> <td style="width: 1%; line-height: 107%">)</td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   Supplemental Cash Flow Information (in thousands)   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">Six Months Ended</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center; line-height: 107%">Operating</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 64%; line-height: 107%">Adoption of ASC 606</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">2,500</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Prepaid stock grants issued to vendors</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">286</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center; line-height: 107%">Investing</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Acquisition of property and equipment in other accrued expenses</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">46</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center; line-height: 107%">Financing</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Settlement of the RedPath Note</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">(8,098</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Issuance of the Exchange Notes</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">11,375</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-cash equity conversion costs</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">(173</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Debt issuance costs</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">(511</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Warrants issued through Termination Agreement*</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">193</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Common shares issued in debt exchange</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">8,869</td> <td style="line-height: 107%"> </td></tr> </table>   *See Note 14, Equity

The net carrying value of the identifiable intangible assets as of June 30, 2018 and December 31, 2017 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As of June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As of December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Life</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Carrying</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Carrying</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">(Years)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Diagnostic assets:</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Asuragen acquisition:</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 34%; padding-left: 10pt; line-height: 107%">Thyroid</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; text-align: center; line-height: 107%"> </td> <td style="width: 10%; text-align: center; line-height: 107%">9</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 22%; text-align: right; line-height: 107%">8,519</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 22%; text-align: right; line-height: 107%">8,519</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">RedPath acquisition:</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Pancreas test</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">7</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">16,141</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">16,141</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Barrett’s test</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">9</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">18,351</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">18,351</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">43,011</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">43,011</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Diagnostic lab:</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">CLIA Lab</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">2.3</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">609</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">609</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Accumulated Amortization</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">(12,140</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">(10,515</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Net Carrying Value</td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">31,480</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">33,105</td> <td style="line-height: 107%"> </td></tr> </table>

Amortization of our diagnostic assets begins upon launch of the product. Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2020</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2021</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2022</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 22%; text-align: right; line-height: 107%">3,252</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">5,292</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 16%; text-align: right; line-height: 107%">5,292</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">4,908</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">2,987</td> <td style="width: 1%; line-height: 107%"> </td></tr> </table>

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, are set forth in the tables below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As of June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="text-align: center; line-height: 107%">Fair Value Measurements</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Carrying</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Fair</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As of June 30, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 1</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 2</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 3</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="18" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Liabilities:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Contingent consideration:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 30%; padding-left: 10pt; line-height: 107%">Asuragen (1)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">1,427</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">1,427</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">1,427</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Other long-term liabilities:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Warrant liability (2)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">407</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">407</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">407</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,834</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,834</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,834</td> <td style="line-height: 107%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As of December 31, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="text-align: center; line-height: 107%">Fair Value Measurements</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Carrying</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">Fair</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">As of December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Value</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 1</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 2</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Level 3</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Liabilities:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Contingent consideration:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 30%; padding-left: 10pt; line-height: 107%">Asuragen (1)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">1,581</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">1,581</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">1,581</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Other long-term liabilities:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Warrant liability (2)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">473</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">473</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">473</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,054</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,054</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,054</td> <td style="line-height: 107%"> </td></tr> </table>   (1)(2) See Note 7, Accrued Expenses and Long-Term Liabilities

A roll forward of the carrying value of the Contingent consideration liability and the Underwriters’ Warrant to June 30, 2018 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Cancellation</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Mark to</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">of Obligation/</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Market</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">June 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Payments</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Accretion</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Conversions</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Adjustment</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="22" style="text-align: center">(unaudited)</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 28%">Asuragen</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">1,581</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">(155</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">1</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 6%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1,427</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Underwriters Warrant</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">473</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(66</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">407</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,054</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(155</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(66</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,834</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Other accrued expenses consisted of the following as of June 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Accrued royalties</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">573</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">296</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Indemnification liability</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">875</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">875</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Contingent consideration</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">316</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">232</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">DOJ settlement</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">150</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">500</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Accrued professional fees</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">690</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">700</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Taxes payable</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">471</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">515</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Unclaimed property</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">565</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">565</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">All others</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">664</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,321</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">4,304</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">5,004</td> <td style="line-height: 107%"> </td></tr> </table>

Long-term liabilities consisted of the following as of June 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 53%; padding-left: 1.5pt; line-height: 107%">Warrant liability</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">407</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">473</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%">Uncertain tax positions</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3,838</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3,734</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 1.5pt; line-height: 107%">Other</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">94</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">82</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 1.5pt; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">4,339</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">4,289</td> <td style="line-height: 107%"> </td></tr> </table>

The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the six-month periods ended June 30, 2018 and 2017.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Six Months Ended</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 60%; line-height: 107%">Risk-free interest rate</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 17%; text-align: right; line-height: 107%">2.65</td> <td style="width: 1%; line-height: 107%">%</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 17%; text-align: right; line-height: 107%">1.96</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected life</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">6.00</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.91</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">126.93</td> <td style="line-height: 107%">%</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">138.71</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Dividend yield</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

IDXG

53598000

51356000

1671000

1680000

-131800000

-134410000

-136910000

-2500000

173062000

174360000

278000

282000

13729000

12804000

1349000

1111000

1394000

938000

391000

1173000

53598000

51356000

31000

33105000

31480000

1172000

1474000

3437000

7647000

6731000

916000

27894000

6877000

27933000

9657000

27894000

6877000

27933000

9657000

-5776000

1626000

813000

Warrants outstanding for the period ended June 30, 2018 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Description</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Classification</td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Exercise Price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Expiration Date</td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants Issued</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants Cancelled/ Expired</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Balance December 31, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Balance June 30, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%; line-height: 107%">Private Placement Warrants, issued January 25, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 7%; line-height: 107%">Equity</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 5%; text-align: right; line-height: 107%">4.69</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 7%; line-height: 107%">June 2022</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 5%; text-align: right; line-height: 107%">855,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 4%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 4%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 4%; text-align: right; line-height: 107%">855,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 4%; text-align: right; line-height: 107%">855,000</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">RedPath Warrants, issued March 22, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Equity</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">4.69</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">September 2022</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">100,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">100,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">100,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Pre-Funded Warrants, issued June 21, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Liability</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.01</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">None</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,600,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(2,600,000</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Underwriters Warrants, issued June 21, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Liability</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.32</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">December 2022</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">575,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(40,000</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">535,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">535,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Base & Overallotment Warrants, issued June 21, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Equity</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.25</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">June 2022</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">14,375,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(5,672,852</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">8,702,148</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">8,702,148</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Vendor Warrants, issued August 6, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Equity</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.25</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">August 2020</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">150,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">150,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">150,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Warrants issued October 12, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">Equity</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">1.80</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">April 2022</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">3,200,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">3,200,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">3,200,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">21,855,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(8,272,852</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(40,000</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">13,542,148</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">13,542,148</td> <td style="line-height: 107%"> </td></tr> </table>

654000

640000

Other Current Assets   Other current assets consisted of the following as of June 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Indemnification asset</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">875</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">875</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Prepaid assets</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">556</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">266</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Other</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">43</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">31</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,474</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,172</td> <td style="line-height: 107%"> </td></tr> </table>

Long-Lived Assets, including Finite-Lived Intangible Assets   Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to nine years in acquisition related amortization expense in the condensed consolidated statements of operations.   The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.

-66000

76000

5000000

5483000

3674000

3254000

1976000

4086000

2691000

2095000

1555000

1019000

719000

518000

413000

10628000

3575000

5152000

5574000

-5145000

99000

-1898000

-3598000

144000

-44000

33000

-8000

-5001000

-4692000

-1865000

-6553000

14000

-298000

8000

-301000

-5015000

-4394000

-1873000

-6252000

-95000

502000

-44000

-54000

2018

116000

94000

782000

-1358000

-220000

40000

-53000

1710000

512000

900000

-2034000

1016000

206000

400000

100000

-61000

117000

25000

1000

271000

1710000

1937000

79000

-79000

15199000

10084000

602000

14265000

-5115000

13663000

-9000

22235000

-0.18

-0.64

-0.07

-0.65

-0.00

0.07

-0.00

-0.01

-0.18

-0.57

-0.07

-0.65

-0.18

-0.64

-0.07

-0.65

-0.00

0.07

-0.00

-0.01

-0.18

-0.57

-0.07

-0.65

2500000 2500000

-944000

-789000

9000

28000

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; font: 12pt Times New Roman, Times, Serif">3.</td> <td style="font: 12pt Times New Roman, Times, Serif">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </td></tr> </table>   Accounting Estimates   The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially differ from those estimates.   Revenue Recognition   Our Services   We are a fully integrated commercial and bioinformatics company that develops and provides clinically useful molecular diagnostic tests and pathology services. We develop and commercialize molecular diagnostic tests and related first line assays principally focused on early detection of patients at high risk of cancer and leverage the latest technology and personalized medicine for improved patient diagnosis and management. We currently have four commercialized molecular diagnostic assays in the marketplace for which we are receiving reimbursement: PancraGEN®, which is a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using our proprietary PathFinderTG® platform; ThyGenX® (now known as ThyGeNEXT™), which is an oncogenic mutation panel that helps identify malignant thyroid nodules; ThyraMIR®, which assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene expression assay; and RespriDX™, launched in September 2017, for assessing metastatic versus primary lung cancer tumors. RespriDX™ also utilizes our PathFinderTG® platform and compares the genetic fingerprint of two or more sites of lung cancer to determine whether the neoplastic deposits are representative of a recurrence of cancer or a new primary (independent) cancer. We are also “soft launching” BarreGEN®, an esophageal cancer risk classifier for Barrett’s Esophagus that also utilizes our PathFinder TG® platform.   Adoption of Accounting Standards Codification Topic 606 (“ASC 606”), “Revenue from Contracts with Customers”   Effective January 1, 2018, the Company adopted ASC 606 which amends the guidance for the recognition of revenue from contracts with customers for the transfer of goods and services, by using the modified-retrospective method applied to any contracts that were not completed as of January 1, 2018. The results for the reporting period beginning after January 1, 2018, are presented in accordance with the new standard, although comparative information has not been restated and continues to be reported under the accounting standards and policies in effect for those periods.   Upon adoption, the Company performed a comprehensive analysis of existing revenue arrangements as of January 1, 2018 following the five-step model outlined in ASC 606. Based on our analysis, we recorded a cumulative adjustment to opening accumulated deficit and increase of accounts receivable of $2.5 million as of January 1, 2018. The cumulative impact was driven by a change in the timing of revenue recognition for certain payer categories and the related proprietary tests performed. The balance of accounts receivable related to the adjustment is approximately $0.9 million as of June 30, 2018.   The following tables present the effect of the adoption of ASC Topic 606 on our condensed consolidated balance sheet and revenue as of and for the six months ended June 30, 2018:   Consolidated Balance Sheet:     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As reported</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Balances without Adoption of ASC 606</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Effect of Change Higher/(Lower)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 43%">Accounts receivable, net</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">7,647</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">6,731</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">916</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Accumulated deficit</td> <td> </td> <td> </td> <td style="text-align: right">(134,410</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(136,910</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(2,500</td> <td>)</td></tr> </table>   Revenue:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">For the six months ended June 30, 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As reported</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Balances without Adoption of ASC 606</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Effect of Change Higher/(Lower)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 43%">Revenue, net</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">10,310</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">9,580</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">730</td> <td style="width: 1%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>     Historically, for certain third-party payers that did not have established contractual reimbursement rates or a predictable pattern of collectability, including commercial insurance carriers, Medicaid and certain direct-bill payers (primarily hospitals, but also laboratories), the Company previously recognized revenues when the fee was fixed or determinable and collectability was reasonably assured, which was upon request of third-party payer notification of payment or when cash was received. Under the new standard, the Company estimates the variable consideration within the transaction price for all third-party payers and proprietary tests and recognizes revenue as the Company satisfies its performance obligations.   In addition, the Company updated its estimates of the expected transaction price and related reimbursement rates for its payer categories and related proprietary tests based on the variable consideration guidance in ASC 606. This consisted of updating the reimbursement rates realized by the Company’s proprietary tests based on historical amounts received by each payer category for the corresponding tests performed.   Overall, other than an initial acceleration in the timing of our revenue recognition for certain payer categories, the adoption of this new standard will not have a significant impact on our reported total revenues and operating results as compared to amounts that would have been reported under the prior revenue recognition standard over our typical revenue cycle. Our accounting policies under the new standard were applied prospectively and are discussed further below.   Revenue Recognition after adoption of ASC 606   Upon adoption of ASC 606, the Company recognizes revenue when a customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience.   The Company derives its revenues from the performance of its proprietary tests. The Company’s performance obligation is fulfilled upon completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the proprietary tests performed. Revenue is recognized based on the estimated transaction price or net realizable value (“NRV”), which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. The Company regularly reviews the ultimate amounts received from the third-party payers and related estimated reimbursement rates and adjusts the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary from our estimates, we will adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known.   Disaggregated Revenues   We operate in a single operating segment and, therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting, which is consistent with internal management reporting. For the six-month periods ended June 30, 2018 and June 30, 2017, the majority of the Company’s revenues were derived from its molecular diagnostic tests.   Financing and Payment   Our payment terms vary by third-party payers and type of proprietary testing services performed. The term between invoicing and when payment is due is not significant.   Costs to Obtain or Fulfill a Customer Contract   Sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in sales and marketing expense in the condensed consolidated statements of operations.   Accounts Receivable   The Company’s accounts receivable represent unconditional rights to consideration and are generated using its proprietary tests. The Company’s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Prior to the adoption of ASC 606 on January 1, 2018, the Company recognized accounts receivable related to billings for Medicare, Medicare Advantage, and direct-bill payers on an accrual basis, net of contractual adjustment, when collectability was reasonably assured. Under ASC 606 accounts receivable is now recognized for all payer groups, net of contractual adjustment and net of estimated uncollectable amounts. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months.   Other Current Assets   Other current assets consisted of the following as of June 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%">Indemnification asset</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">875</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">875</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Prepaid assets</td> <td> </td> <td> </td> <td style="text-align: right">556</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">266</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Other</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">43</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">31</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,474</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,172</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Long-Lived Assets, including Finite-Lived Intangible Assets   Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to nine years in acquisition related amortization expense in the condensed consolidated statements of operations.   The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.   Discontinued Operations   The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations (“ASC 205-20”). ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note 11, Discontinued Operations for further information.   Basic and Diluted Net Loss per Share   A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and six-month periods ended June 30, 2018 and 2017 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="text-align: center">Three Months Ended</td> <td> </td> <td> </td> <td colspan="6" style="text-align: center">Six Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">(unaudited)</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Basic weighted average number of common shares</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">27,933</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">9,657</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">27,894</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">6,877</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Potential dilutive effect of stock-based awards</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Diluted weighted average number of common shares</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">27,933</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,657</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">27,894</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,877</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The following outstanding stock-based instruments were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="text-align: center">Three Months Ended</td> <td> </td> <td> </td> <td colspan="6" style="text-align: center">Six Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">(unaudited)</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2,256</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">323</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2,256</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">323</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock-settled stock appreciation rights (SARs)</td> <td> </td> <td> </td> <td style="text-align: right">59</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">85</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">59</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">85</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Restricted stock units (RSUs)</td> <td> </td> <td> </td> <td style="text-align: right">220</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">68</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">220</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">68</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">13,542</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">17,105</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">13,542</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">17,105</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">16,077</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">17,581</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">16,077</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">17,581</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Accounting Estimates   The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially differ from those estimates.

Revenue Recognition   Our Services   We are a fully integrated commercial and bioinformatics company that develops and provides clinically useful molecular diagnostic tests and pathology services. We develop and commercialize molecular diagnostic tests and related first line assays principally focused on early detection of patients at high risk of cancer and leverage the latest technology and personalized medicine for improved patient diagnosis and management. We currently have four commercialized molecular diagnostic assays in the marketplace for which we are receiving reimbursement: PancraGEN®, which is a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using our proprietary PathFinderTG® platform; ThyGenX® (now known as ThyGeNEXT™), which is an oncogenic mutation panel that helps identify malignant thyroid nodules; ThyraMIR®, which assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene expression assay; and RespriDX™, launched in September 2017, for assessing metastatic versus primary lung cancer tumors. RespriDX™ also utilizes our PathFinderTG® platform and compares the genetic fingerprint of two or more sites of lung cancer to determine whether the neoplastic deposits are representative of a recurrence of cancer or a new primary (independent) cancer. We are also “soft launching” BarreGEN®, an esophageal cancer risk classifier for Barrett’s Esophagus that also utilizes our PathFinder TG® platform.   Adoption of Accounting Standards Codification Topic 606 (“ASC 606”), “Revenue from Contracts with Customers”   Effective January 1, 2018, the Company adopted ASC 606 which amends the guidance for the recognition of revenue from contracts with customers for the transfer of goods and services, by using the modified-retrospective method applied to any contracts that were not completed as of January 1, 2018. The results for the reporting period beginning after January 1, 2018, are presented in accordance with the new standard, although comparative information has not been restated and continues to be reported under the accounting standards and policies in effect for those periods.   Upon adoption, the Company performed a comprehensive analysis of existing revenue arrangements as of January 1, 2018 following the five-step model outlined in ASC 606. Based on our analysis, we recorded a cumulative adjustment to opening accumulated deficit and increase of accounts receivable of $2.5 million as of January 1, 2018. The cumulative impact was driven by a change in the timing of revenue recognition for certain payer categories and the related proprietary tests performed. The balance of accounts receivable related to the adjustment is approximately $0.9 million as of June 30, 2018.   The following tables present the effect of the adoption of ASC Topic 606 on our condensed consolidated balance sheet and revenue as of and for the six months ended June 30, 2018:   Consolidated Balance Sheet:     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As reported</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Balances without Adoption of ASC 606</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Effect of Change Higher/(Lower)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 43%">Accounts receivable, net</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">7,647</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">6,731</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">916</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Accumulated deficit</td> <td> </td> <td> </td> <td style="text-align: right">(134,410</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(136,910</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(2,500</td> <td>)</td></tr> </table>   Revenue:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">For the six months ended June 30, 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As reported</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Balances without Adoption of ASC 606</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Effect of Change Higher/(Lower)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 43%">Revenue, net</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">10,310</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">9,580</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">730</td> <td style="width: 1%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>     Historically, for certain third-party payers that did not have established contractual reimbursement rates or a predictable pattern of collectability, including commercial insurance carriers, Medicaid and certain direct-bill payers (primarily hospitals, but also laboratories), the Company previously recognized revenues when the fee was fixed or determinable and collectability was reasonably assured, which was upon request of third-party payer notification of payment or when cash was received. Under the new standard, the Company estimates the variable consideration within the transaction price for all third-party payers and proprietary tests and recognizes revenue as the Company satisfies its performance obligations.   In addition, the Company updated its estimates of the expected transaction price and related reimbursement rates for its payer categories and related proprietary tests based on the variable consideration guidance in ASC 606. This consisted of updating the reimbursement rates realized by the Company’s proprietary tests based on historical amounts received by each payer category for the corresponding tests performed.   Overall, other than an initial acceleration in the timing of our revenue recognition for certain payer categories, the adoption of this new standard will not have a significant impact on our reported total revenues and operating results as compared to amounts that would have been reported under the prior revenue recognition standard over our typical revenue cycle. Our accounting policies under the new standard were applied prospectively and are discussed further below.   Revenue Recognition after adoption of ASC 606   Upon adoption of ASC 606, the Company recognizes revenue when a customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience.   The Company derives its revenues from the performance of its proprietary tests. The Company’s performance obligation is fulfilled upon completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the proprietary tests performed. Revenue is recognized based on the estimated transaction price or net realizable value (“NRV”), which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. The Company regularly reviews the ultimate amounts received from the third-party payers and related estimated reimbursement rates and adjusts the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary from our estimates, we will adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known.   Disaggregated Revenues   We operate in a single operating segment and, therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting, which is consistent with internal management reporting. For the six-month periods ended June 30, 2018 and June 30, 2017, the majority of the Company’s revenues were derived from its molecular diagnostic tests.   Financing and Payment   Our payment terms vary by third-party payers and type of proprietary testing services performed. The term between invoicing and when payment is due is not significant.   Costs to Obtain or Fulfill a Customer Contract   Sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in sales and marketing expense in the condensed consolidated statements of operations.

Accounts Receivable   The Company’s accounts receivable represent unconditional rights to consideration and are generated using its proprietary tests. The Company’s services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Prior to the adoption of ASC 606 on January 1, 2018, the Company recognized accounts receivable related to billings for Medicare, Medicare Advantage, and direct-bill payers on an accrual basis, net of contractual adjustment, when collectability was reasonably assured. Under ASC 606 accounts receivable is now recognized for all payer groups, net of contractual adjustment and net of estimated uncollectable amounts. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months.

Discontinued Operations   The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations (“ASC 205-20”). ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. See Note 11, Discontinued Operations for further information.

Basic and Diluted Net Loss per Share   A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and six-month periods ended June 30, 2018 and 2017 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">Three Months Ended</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">Six Months Ended</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30,</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="14" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 107%">Basic weighted average number of common shares</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">27,933</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">9,657</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">27,894</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">6,877</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Potential dilutive effect of stock-based awards</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Diluted weighted average number of common shares</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">27,933</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">9,657</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">27,894</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">6,877</td> <td style="line-height: 107%"> </td></tr> </table>   The following outstanding stock-based instruments were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">Three Months Ended</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">Six Months Ended</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30,</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="14" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 107%">Options</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">2,256</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">323</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">2,256</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">323</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Stock-settled stock appreciation rights (SARs)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">59</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">85</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">59</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">85</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Restricted stock units (RSUs)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">220</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">68</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">220</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">68</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">13,542</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">17,105</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">13,542</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">17,105</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">16,077</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">17,581</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">16,077</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">17,581</td> <td style="line-height: 107%"> </td></tr> </table>

The following table summarizes income tax expense on (loss) income from continuing operations and the effective tax rate for the three- and six-month periods ended June 30, 2018 and 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">Three Months Ended</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">Six Months Ended</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30,</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%; line-height: 107%">Provision (benefit) from income tax</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">8</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">(301</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">14</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">(298</td> <td style="width: 1%; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Effective income tax rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(0.4</td> <td style="line-height: 107%">)%</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.6</td> <td style="line-height: 107%">%</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(0.3</td> <td style="line-height: 107%">)%</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">6.4</td> <td style="line-height: 107%">%</td></tr> </table>

4289000

4339000

-456000

-1549000

The components of liabilities classified as discontinued operations relate to Commercial Services and consist of the following as of June 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">June 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">(unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%; line-height: 107%">Accounts payable</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">192</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">192</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Other</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">747</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,110</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Current liabilities from discontinued operations</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">939</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,302</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Total liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">939</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,302</td> <td style="line-height: 107%"> </td></tr> </table>

28194275

27901000

64000

28267000

73000

286000

4000

282000

9000

1016000

The following tables present the effect of the adoption of ASC Topic 606 on our condensed consolidated balance sheet and revenue as of and for the six months ended June 30, 2018:   Consolidated Balance Sheet:     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As reported</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Balances without Adoption of ASC 606</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Effect of Change Higher/(Lower)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 43%">Accounts receivable, net</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">7,647</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">6,731</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">916</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Accumulated deficit</td> <td> </td> <td> </td> <td style="text-align: right">(134,410</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(136,910</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(2,500</td> <td>)</td></tr> </table>   Revenue:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">For the six months ended June 30, 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As reported</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Balances without Adoption of ASC 606</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Effect of Change Higher/(Lower)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 43%">Revenue, net</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">10,310</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">9,580</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">730</td> <td style="width: 1%"> </td></tr> </table>

Other current assets consisted of the following as of June 30, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%">Indemnification asset</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">875</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">875</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Prepaid assets</td> <td> </td> <td> </td> <td style="text-align: right">556</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">266</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Other</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">43</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">31</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,474</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,172</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and six-month periods ended June 30, 2018 and 2017 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="text-align: center">Three Months Ended</td> <td> </td> <td> </td> <td colspan="6" style="text-align: center">Six Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">(unaudited)</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Basic weighted average number of common shares</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">27,933</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">9,657</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">27,894</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">6,877</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Potential dilutive effect of stock-based awards</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Diluted weighted average number of common shares</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">27,933</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,657</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">27,894</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6,877</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following outstanding stock-based instruments were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="text-align: center">Three Months Ended</td> <td> </td> <td> </td> <td colspan="6" style="text-align: center">Six Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">(unaudited)</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2,256</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">323</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2,256</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">323</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock-settled stock appreciation rights (SARs)</td> <td> </td> <td> </td> <td style="text-align: right">59</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">85</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">59</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">85</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Restricted stock units (RSUs)</td> <td> </td> <td> </td> <td style="text-align: right">220</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">68</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">220</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">68</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">13,542</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">17,105</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">13,542</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">17,105</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">16,077</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">17,581</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">16,077</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">17,581</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

9000

10310000

7325000

5501000

3855000

4827000

3651000

2247000

1879000

-350000

19808000

19205000

8091000

7354000

-5027000

-8572000

2500000

P9Y

P7Y

P9Y

P2Y3M19D

P2Y

P9Y

10310000

9580000

730000

875000

266000

556000

31000

43000

16077000

17851000

323000

85000

68000

2256000

59000

220000

13542000

17105000

16077000

17581000

2256000

59000

220000

13542000

323000

85000

68000

17105000

1626000

813000

8519000

16141000

18351000

43011000

609000

43011000

-10515000

-12140000

33105000

31480000

3252000

5292000

4908000

2987000

2600000

575000

1581000

1427000

1581000

1427000

473000 473000 473000 407000 407000 407000

2054000

1834000

2054000

1834000

1581000

473000

1427000

407000

155000

1000 1000

-66000

500000

3000000

500000

150000

500000

636053

11375000

1000000

Extend it through June 30, 2023 20000

33333

41667

The lease is for 20,000 square feet of laboratory and office space, with monthly base rent of $33,333 beginning July 1, 2018, escalating by twenty-five percent (25%) on July 1, 2019 to $41,667 per month. The Company may, at its option, extend the term of the Lease for two consecutive terms of five years each, with the monthly based rent escalating by ten percent (10%) for each of the additional five year terms.

296000

573000

875000

232000

316000

500000

150000

700000

690000

5004000

4304000

3734000

3838000

82000

94000

Stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for employees and members of the Board of Directors. Upon exercise, new shares will be issued by the Company. The Company granted stock options in 2018 and 2017 which vest monthly over a one-year period. SARs are generally granted with a grant price equal to the market value of the common stock on the date of grant, vest one-third each year on the anniversary of the date of grant and expire five years from the date of grant. The restricted shares and restricted stock units granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.

P3Y

745600

186400

1.01

0.0265

0.0196

P6Y

P4Y10M28D

1.2693

1.3871

0.00

-0.003

0.064

-0.004

0.046

192000

1110000

747000

1302000

939000

3795429

-354000

-883000

286000

46000

12300000

8869000

855000

100000

12500000

2600000

12200000

P5Y

4.69

0.01

4.69

1.25

1.80

1.32

1.25

0.01

Each Firm Share and accompanying Base Warrant was sold for a combined effective price of $1.10, and each Pre-Funded Warrant and accompanying Base Warrant was sold for a combined effective price of $1.09. 13700000

Pre-Funded Warrants, issued June 21, 2017

Private Placement Warrants, issued January 25, 2017

RedPath Warrants, issued March 22, 2017

Base & Overallotment Warrants, issued June 21, 2017

Vendor Warrants, issued August 6, 2017

Warrants issued october 12 2017

Underwriters Warrants, issued June 21, 2017

Liability Equity Equity Equity Equity Equity Liability None June 2022 September 2022 June 2022 August 2020 April 2022 December 2022

21855000

2600000

855000

100000

14375000

150000

3200000

575000

-8272852 -2600000 -5672852

40000

13542148

100000

535000

855000

8702148

150000

3200000

535000

855000

100000

8702148

150000

3200000

P3Y

4000000

0.80 850000

515000

471000

1321000 664000 565000 565000 473000 407000

511000

193000 -173000 -8098000

24000

See Note 7, Accrued Expenses and Long-Term Liabilities See Note 14, Equity

EX-101.SCH 7 idxg-20180630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Stockholder's Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Accrued Expenses and Long-Term Liabilities link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Accrued Expenses and Long-Term Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Liquidity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Effect of Adoption of ASC Topic 606 on Condensed Consolidated Balance Sheet and Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Summary of Significant Accounting Policies - Schedule of Weighted Average Number of Shares (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Other Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Other Intangible Assets - Schedule of Future Estimated Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Fair Value Measurements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Fair Value Measurements - Schedule of Financial Instrument Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Accrued Expenses and Long-Term Liabilities - Schedule of Other Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Accrued Expenses and Long-Term Liabilities - Schedule of Long Term Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Stock-Based Compensation - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Segment Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations Amount Recognized in Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Long-Term Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Disclosure of Cash flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Warrants - Schedule of Warrants Outstanding and Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 idxg-20180630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 idxg-20180630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 idxg-20180630_lab.xml XBRL LABEL FILE Finite-Lived Intangible Assets by Major Class [Axis] Diagnostic Assets, Thyroid [Member] Business Acquisition [Axis] Asuragen Acquisition [Member] Diagnostic Assets, Pancreas Test [Member] RedPath Acquisition [Member] Diagnostic Assets, Barrett's Test [Member] Diagnostic Lab, CLIA Lab [Member] Diagnostic Assets [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Measurements [Member] Litigation Case [Axis] Companys Counter-Claim Against Prolias [Member] Equity Components [Axis] Common Stock [Member] Treasury Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] RedPath Warrants[Member] Pre-Funded Warrants [Member] Underwriter Warrants[Member] Measurement Basis [Axis] Reported Value Measurement [Member] Level 1 [Member] Level 2 [Member] Level 3 [Member] Legal Entity [Axis] Asuragen [Member] Underwriter Warrants [Member] Private Placement Warrants[Member] Base & Overallotment Warrants [Member] Vendor Warrants [Member] Warrants Issued [Member] Range [Axis] Minimum [Member] Maximum [Member] Scenario [Axis] Adoption of ASC Topic 606 [Member] Balances without Adoption of ASC 606 [Member] Effect of Change Higher/(Lower) [Member] Antidilutive Securities [Axis] Options [Member] Stock-Settled Stock Appreciation Rights (SARs) [Member] Restricted Stock Units (RSUs) [Member] Warrants [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Settlement Agreement [Member] RedPath [Member] Lease Arrangement, Type [Axis] Pittsburgh Lease [Member] July 1, 2018 [Member] July 1, 2019 [Member] Plan Name [Axis] Stock Incentive Plan [Member] Exchange Agreement [Member] Debt Instrument [Axis] Senior Convertible Notes [Member] March 23, 2017 and April 18, 2017 [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] RedPath Debt Exchange and conversion of Senior Convertible Notes [Member] Termination Agreement [Member] RedPath Equityholder Representative, LLC [Member] Base Warrants [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Accounts receivable, net Other current assets Total current assets Property and equipment, net Other intangible assets, net Other long-term assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued salaries and bonus Other accrued expenses Current liabilities from discontinued operations Total current liabilities Contingent consideration Other long-term liabilities Total liabilities Commitments and contingencies (Note 6) Stockholders' equity: Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding Common stock, $.01 par value; 100,000,000 shares authorized; 28,267,344 and 27,900,806 shares issued, respectively; 28,194,275 and 27,836,456 shares outstanding, respectively Additional paid-in capital Accumulated deficit Treasury stock, at cost (73,069 and 64,350 shares, respectively) Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, shares Income Statement [Abstract] Revenue, net Cost of revenue (excluding amortization of $813 and $813 for the three months and $1,626 and $1,626 for the six months, respectively) Gross profit Operating expenses: Sales and marketing Research and development General and administrative Acquisition related amortization expense Change in fair value of contingent consideration Total operating expenses Operating (loss) income Interest expense Loss on extinguishment of debt Other income (expense), net Loss from continuing operations before tax Provision (benefit) for income taxes Loss from continuing operations (Loss) income from discontinued operations, net of tax Net loss Basic (loss) income per share of common stock: From continuing operations From discontinued operations Net loss per basic share of common stock Diluted (loss) income per share of common stock: From continuing operations From discontinued operations Net loss per diluted share of common stock Weighted average number of common shares and common share equivalents outstanding: Basic Diluted Cost of revenue, amortization Statement [Table] Statement [Line Items] Balance Balance, shares Common stock issued Common stock issued, shares Treasury stock purchased Treasury stock purchased, shares Stock-based compensation expense Net loss Adoption of ASC 606 Balance Balance, shares Statement of Cash Flows [Abstract] Cash Flows Used in Operating Activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Interest accretion Provision for bad debt Amortization of debt issuance costs Mark to market on derivatives Reversal of severance accrual Reversal of DOJ accrual Mark to market on warrants Loss on extinguishment of debt Stock-based compensation, consulting agreements Stock-based compensation Other changes in assets and liabilities: Increase in accounts receivable (Increase) decrease in other current assets Decrease in other long-term assets Increase (decrease) in accounts payable Decrease in accrued salaries and bonus Decrease in other accrued expenses Increase in other long-term liabilities Net cash used in operating activities Cash Flows Used in Investing Activities Purchase of property and equipment Net cash used in investing activities Cash Flows Used in Financing Activities Issuance of common stock, net of expenses Cash paid for repurchase of restricted shares Net cash (used in) provided by financing activities Net (decrease) increase in cash and cash equivalents Cash and cash equivalents - beginning EX-101.PRE 11 idxg-20180630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Aug. 03, 2018
Document And Entity Information
Entity Registrant Name	Interpace Diagnostics Group, Inc.
Entity Central Index Key	0001054102
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		28,194,275
Trading Symbol	IDXG
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2018

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 10,084	$ 15,199
Accounts receivable, net	7,647	3,437
Other current assets	1,474	1,172
Total current assets	19,205	19,808
Property and equipment, net	640	654
Other intangible assets, net	31,480	33,105
Other long-term assets	31	31
Total assets	51,356	53,598
Current liabilities:
Accounts payable	1,173	391
Accrued salaries and bonus	938	1,394
Other accrued expenses	4,304	5,004
Current liabilities from discontinued operations	939	1,302
Total current liabilities	7,354	8,091
Contingent consideration	1,111	1,349
Other long-term liabilities	4,339	4,289
Total liabilities	12,804	13,729
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $.01 par value; 100,000,000 shares authorized; 28,267,344 and 27,900,806 shares issued, respectively; 28,194,275 and 27,836,456 shares outstanding, respectively	282	278
Additional paid-in capital	174,360	173,062
Accumulated deficit	(134,410)	(131,800)
Treasury stock, at cost (73,069 and 64,350 shares, respectively)	(1,680)	(1,671)
Total stockholders' equity	38,552	39,869
Total liabilities and stockholders' equity	$ 51,356	$ 53,598

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ .01	$ .01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	28,267,344	27,900,806
Common stock, shares outstanding	28,194,275	27,836,456
Treasury stock, shares	73,069	64,350

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Revenue, net	$ 5,501	$ 3,855	$ 10,310	$ 7,325
Cost of revenue (excluding amortization of $813 and $813 for the three months and $1,626 and $1,626 for the six months, respectively)	2,247	1,879	4,827	3,651
Gross profit	3,254	1,976	5,483	3,674
Operating expenses:
Sales and marketing	2,095	1,555	4,086	2,691
Research and development	518	413	1,019	719
General and administrative	1,726	2,793	3,897	4,315
Acquisition related amortization expense	813	813	1,626	1,626
Change in fair value of contingent consideration				(5,776)
Total operating expenses	5,152	5,574	10,628	3,575
Operating (loss) income	(1,898)	(3,598)	(5,145)	99
Interest expense		(216)		(469)
Loss on extinguishment of debt		(2,731)		(4,278)
Other income (expense), net	33	(8)	144	(44)
Loss from continuing operations before tax	(1,865)	(6,553)	(5,001)	(4,692)
Provision (benefit) for income taxes	8	(301)	14	(298)
Loss from continuing operations	(1,873)	(6,252)	(5,015)	(4,394)
(Loss) income from discontinued operations, net of tax	(44)	(54)	(95)	502
Net loss	$ (1,917)	$ (6,306)	$ (5,110)	$ (3,892)
Basic (loss) income per share of common stock:
From continuing operations	$ (0.07)	$ (0.65)	$ (0.18)	$ (0.64)
From discontinued operations	(0.00)	(0.01)	(0.00)	0.07
Net loss per basic share of common stock	(0.07)	(0.65)	(0.18)	(0.57)
Diluted (loss) income per share of common stock:
From continuing operations	(0.07)	(0.65)	(0.18)	(0.64)
From discontinued operations	(0.00)	(0.01)	(0.00)	0.07
Net loss per diluted share of common stock	$ (0.07)	$ (0.65)	$ (0.18)	$ (0.57)
Weighted average number of common shares and common share equivalents outstanding:
Basic	27,933,000	9,657,000	27,894,000	6,877,000
Diluted	27,933,000	9,657,000	27,894,000	6,877,000

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Cost of revenue, amortization	$ 813	$ 813	$ 1,626	$ 1,626

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholder's Equity (Unaudited) - 6 months ended Jun. 30, 2018 - USD ($) $ in Thousands	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 278	$ (1,671)	$ 173,062	$ (131,800)	$ 39,869
Balance, shares at Dec. 31, 2017	27,901,000	64,000
Common stock issued	$ 4		282		286
Common stock issued, shares	366,000
Treasury stock purchased		$ (9)			(9)
Treasury stock purchased, shares		9,000
Stock-based compensation expense			1,016		1,016
Net loss				(5,110)	(5,110)
Adoption of ASC 606				2,500	2,500
Balance at Jun. 30, 2018	$ 282	$ (1,680)	$ 174,360	$ (134,410)	$ 38,552
Balance, shares at Jun. 30, 2018	28,267,000	73,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash Flows Used in Operating Activities
Net loss	$ (5,110)	$ (3,892)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,710	1,937
Interest accretion	1	271
Provision for bad debt		25
Amortization of debt issuance costs		117
Mark to market on derivatives		61
Reversal of severance accrual		(2,034)
Reversal of DOJ accrual	(350)
Mark to market on warrants	(66)	76
Loss on extinguishment of debt		4,278
Stock-based compensation, consulting agreements	24
Stock-based compensation	1,016	206
Change in fair value of contingent consideration		(5,776)
Other changes in assets and liabilities:
Increase in accounts receivable	(1,710)	(512)
(Increase) decrease in other current assets	(40)	53
Decrease in other long-term assets		220
Increase (decrease) in accounts payable	782	(1,358)
Decrease in accrued salaries and bonus	(456)	(1,549)
Decrease in other accrued expenses	(944)	(789)
Increase in other long-term liabilities	116	94
Net cash used in operating activities	(5,027)	(8,572)
Cash Flows Used in Investing Activities
Purchase of property and equipment	(79)
Net cash used in investing activities	(79)
Cash Flows Used in Financing Activities
Issuance of common stock, net of expenses		22,263
Cash paid for repurchase of restricted shares	(9)	(28)
Net cash (used in) provided by financing activities	(9)	22,235
Net (decrease) increase in cash and cash equivalents	(5,115)	13,663
Cash and cash equivalents - beginning	15,199	602
Cash and cash equivalents - ending	$ 10,084	$ 14,265

XML 19 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

1.	BASIS OF PRESENTATION

XML 20 R9.htm IDEA: XBRL DOCUMENT

Liquidity

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Liquidity

2.	LIQUIDITY

XML 21 R10.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

3.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Estimates

Revenue Recognition

Our Services

Adoption of Accounting Standards Codification Topic 606 (“ASC 606”), “Revenue from Contracts with Customers”

The following tables present the effect of the adoption of ASC Topic 606 on our condensed consolidated balance sheet and revenue as of and for the six months ended June 30, 2018:

Consolidated Balance Sheet:

	June 30, 2018
				(unaudited)
	As reported			Balances without Adoption of ASC 606			Effect of Change Higher/(Lower)
Accounts receivable, net	$	7,647		$	6,731		$	916
Accumulated deficit		(134,410	)		(136,910	)		(2,500	)

Revenue:

	For the six months ended June 30, 2018
			(unaudited)
	As reported		Balances without Adoption of ASC 606		Effect of Change Higher/(Lower)
Revenue, net	$	10,310	$	9,580	$	730

Revenue Recognition after adoption of ASC 606

Disaggregated Revenues

Financing and Payment

Our payment terms vary by third-party payers and type of proprietary testing services performed. The term between invoicing and when payment is due is not significant.

Costs to Obtain or Fulfill a Customer Contract

Accounts Receivable

Other Current Assets

Other current assets consisted of the following as of June 30, 2018 and December 31, 2017:

	June 30, 2018		December 31, 2017
	(unaudited)

Indemnification asset	$	875	$	875
Prepaid assets		556		266
Other		43		31
	$	1,474	$	1,172

Long-Lived Assets, including Finite-Lived Intangible Assets

Discontinued Operations

Basic and Diluted Net Loss per Share

A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and six-month periods ended June 30, 2018 and 2017 is as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2018		2017		2018		2017
	(unaudited)

Basic weighted average number of common shares		27,933		9,657		27,894		6,877
Potential dilutive effect of stock-based awards		-		-		-		-
Diluted weighted average number of common shares		27,933		9,657		27,894		6,877

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2018		2017		2018		2017
	(unaudited)

Options		2,256		323		2,256		323
Stock-settled stock appreciation rights (SARs)		59		85		59		85
Restricted stock units (RSUs)		220		68		220		68
Warrants		13,542		17,105		13,542		17,105
		16,077		17,581		16,077		17,581

XML 22 R11.htm IDEA: XBRL DOCUMENT

Other Intangible Assets

6 Months Ended

Jun. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Other Intangible Assets

4.	OTHER INTANGIBLE ASSETS

The net carrying value of the identifiable intangible assets as of June 30, 2018 and December 31, 2017 are as follows:

			As of June 30, 2018			As of December 31, 2017
			(unaudited)
	Life		Carrying			Carrying
	(Years)		Amount			Amount
Diagnostic assets:
Asuragen acquisition:
Thyroid		9	$	8,519		$	8,519
RedPath acquisition:
Pancreas test		7		16,141			16,141
Barrett’s test		9		18,351			18,351
Total			$	43,011		$	43,011
Diagnostic lab:
CLIA Lab		2.3	$	609		$	609

Accumulated Amortization			$	(12,140	)	$	(10,515	)

Net Carrying Value			$	31,480		$	33,105

2018				2019				2020				2021				2022
$	3,252			$	5,292			$	5,292			$	4,908			$	2,987

XML 23 R12.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

5.	FAIR VALUE MEASUREMENTS

	Level 1:	Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.

	Level 2:	Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.

	Level 3:	Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.

	As of June 30, 2018				Fair Value Measurements
	Carrying		Fair		As of June 30, 2018
	Amount		Value		Level 1		Level 2		Level 3
	(unaudited)
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	1,427	$	1,427	$	-	$	-	$	1,427
Other long-term liabilities:
Warrant liability ⁽²⁾		407		407		-		-		407
	$	1,834	$	1,834	$	-	$	-	$	1,834

	As of December 31, 2017				Fair Value Measurements
	Carrying		Fair		As of December 31, 2017
	Amount		Value		Level 1		Level 2		Level 3
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	1,581	$	1,581	$	-	$	-	$	1,581
Other long-term liabilities:
Warrant liability ⁽²⁾		473		473		-		-		473
	$	2,054	$	2,054	$	-	$	-	$	2,054

⁽¹⁾⁽²⁾See Note 7, Accrued Expenses and Long-Term Liabilities

A roll forward of the carrying value of the Contingent consideration liability and the Underwriters’ Warrant to June 30, 2018 is as follows:

								Cancellation		Mark to
	December 31,							of Obligation/		Market			June 30,
	2017		Payments			Accretion		Conversions		Adjustment			2018
	(unaudited)

Asuragen	$	1,581	$	(155	)	$	1	$	-	$	-		$	1,427

Underwriters Warrant		473		-					-		(66	)		407
	$	2,054	$	(155	)	$	1	$	-	$	(66	)	$	1,834

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

6.	COMMITMENTS AND CONTINGENCIES

Litigation

As of June 30, 2018, the Company’s accrual for litigation and threatened litigation was not material to the condensed consolidated financial statements.

RedPath – DOJ Settlement

Prolias Technologies, Inc. v. PDI, Inc.

Pittsburgh Lease

XML 25 R14.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Long-Term Liabilities

6 Months Ended

Jun. 30, 2018

Payables and Accruals [Abstract]

Accrued Expenses and Long-Term Liabilities

7.	ACCRUED EXPENSES AND LONG-TERM LIABILITIES

Other accrued expenses consisted of the following as of June 30, 2018 and December 31, 2017:

	June 30, 2018		December 31, 2017
		(unaudited)

Accrued royalties	$	573	$	296
Indemnification liability		875		875
Contingent consideration		316		232
DOJ settlement		150		500
Accrued professional fees		690		700
Taxes payable		471		515
Unclaimed property		565		565
All others		664		1,321
	$	4,304	$	5,004

Long-term liabilities consisted of the following as of June 30, 2018 and December 31, 2017:

	June 30, 2018		December 31, 2017
	(unaudited)

Warrant liability	$	407	$	473
Uncertain tax positions		3,838		3,734
Other		94		82
	$	4,339	$	4,289

XML 26 R15.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

8.	STOCK-BASED COMPENSATION

Stock Incentive Plan

The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the six-month periods ended June 30, 2018 and 2017.

	Six Months Ended
	June 30, 2018			June 30, 2017
	(unaudited)

Risk-free interest rate		2.65	%		1.96	%
Expected life		6.00			4.91
Expected volatility		126.93	%		138.71	%
Dividend yield		-			-

XML 27 R16.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2018

Income Tax Disclosure [Abstract]

Income Taxes

9.	INCOME TAXES

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2018			2017			2018			2017
	(unaudited)						(unaudited)

Provision (benefit) from income tax	$	8		$	(301	)	$	14		$	(298	)
Effective income tax rate		(0.4	)%		4.6	%		(0.3	)%		6.4	%

Income tax expense for the three- and six-month periods ended June 30, 2018 was primarily due to minimum state and local taxes.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Segment Information

6 Months Ended

Jun. 30, 2018

Segment Reporting [Abstract]

Segment Information

10.

SEGMENT INFORMATION

XML 29 R18.htm IDEA: XBRL DOCUMENT

Discontinued Operations

6 Months Ended

Jun. 30, 2018

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

11.

DISCONTINUED OPERATIONS

The components of liabilities classified as discontinued operations relate to Commercial Services and consist of the following as of June 30, 2018 and December 31, 2017:

	June 30, 2018		December 31, 2017
	(unaudited)

Accounts payable	$	192	$	192
Other		747		1,110
Current liabilities from discontinued operations		939		1,302
Total liabilities	$	939	$	1,302

XML 30 R19.htm IDEA: XBRL DOCUMENT

Long-Term Debt

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

Long-Term Debt

12.

LONG-TERM DEBT

The Company has no long-term debt.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information

6 Months Ended

Jun. 30, 2018

Supplemental Cash Flow Elements [Abstract]

Supplemental Cash Flow Information

13.

SUPPLEMENTAL CASH FLOW INFORMATION

The following table presents cash flows used in the Company’s discontinued operations for the six months ended June 30, 2018 and 2017:

	Six Months Ended
	June 30,
	2018			2017
	(unaudited)
Net cash used in operating activities of discontinued operations	$	(354	)	$	(883	)

Supplemental Cash Flow Information

(in thousands)

	Six Months Ended
	June 30,
	2018		2017
	(unaudited)
Operating
Adoption of ASC 606	$	2,500	$	-
Prepaid stock grants issued to vendors	$	286	$	-

Investing
Acquisition of property and equipment in other accrued expenses	$	46	$	-

Financing
Settlement of the RedPath Note	$	-	$	(8,098	)
Issuance of the Exchange Notes	$	-	$	11,375
Non-cash equity conversion costs	$	-	$	(173	)
Debt issuance costs	$	-	$	(511	)
Warrants issued through Termination Agreement*	$	-	$	193
Common shares issued in debt exchange	$	-	$	8,869

*See Note 14, Equity

XML 32 R21.htm IDEA: XBRL DOCUMENT

Equity

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Equity

14.

EQUITY

XML 33 R22.htm IDEA: XBRL DOCUMENT

Warrants

6 Months Ended

Jun. 30, 2018

Warrants

Warrants

15.

WARRANTS

There was no warrant activity for the six months ended June 30, 2018. Warrants outstanding for the period ended June 30, 2018 are as follows:

Description	Classification	Exercise Price		Expiration Date	Warrants Issued		Warrants Exercised			Warrants Cancelled/ Expired			Balance December 31, 2017		Balance June 30, 2018

Private Placement Warrants, issued January 25, 2017	Equity	$	4.69	June 2022		855,000		-			-			855,000		855,000
RedPath Warrants, issued March 22, 2017	Equity	$	4.69	September 2022		100,000		-			-			100,000		100,000
Pre-Funded Warrants, issued June 21, 2017	Liability	$	0.01	None		2,600,000		(2,600,000	)		-			-		-
Underwriters Warrants, issued June 21, 2017	Liability	$	1.32	December 2022		575,000		-			(40,000	)		535,000		535,000
Base & Overallotment Warrants, issued June 21, 2017	Equity	$	1.25	June 2022		14,375,000		(5,672,852	)		-			8,702,148		8,702,148
Vendor Warrants, issued August 6, 2017	Equity	$	1.25	August 2020		150,000		-			-			150,000		150,000
Warrants issued October 12, 2017	Equity	$	1.80	April 2022		3,200,000		-			-			3,200,000		3,200,000

						21,855,000		(8,272,852	)		(40,000	)		13,542,148		13,542,148

XML 34 R23.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

6 Months Ended

Jun. 30, 2018

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements

16.

RECENT ACCOUNTING PRONOUNCEMENTS

Recently adopted standards

New standards not yet adopted

XML 35 R24.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2018

Subsequent Events [Abstract]

Subsequent Events

17.

SUBSEQUENT EVENTS

Nasdaq Correspondence

Line of credit

XML 36 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Accounting Estimates

Accounting Estimates

Revenue Recognition

Revenue Recognition

Our Services

Adoption of Accounting Standards Codification Topic 606 (“ASC 606”), “Revenue from Contracts with Customers”

The following tables present the effect of the adoption of ASC Topic 606 on our condensed consolidated balance sheet and revenue as of and for the six months ended June 30, 2018:

Consolidated Balance Sheet:

	June 30, 2018
				(unaudited)
	As reported			Balances without Adoption of ASC 606			Effect of Change Higher/(Lower)
Accounts receivable, net	$	7,647		$	6,731		$	916
Accumulated deficit		(134,410	)		(136,910	)		(2,500	)

Revenue:

	For the six months ended June 30, 2018
			(unaudited)
	As reported		Balances without Adoption of ASC 606		Effect of Change Higher/(Lower)
Revenue, net	$	10,310	$	9,580	$	730

Revenue Recognition after adoption of ASC 606

Disaggregated Revenues

Financing and Payment

Our payment terms vary by third-party payers and type of proprietary testing services performed. The term between invoicing and when payment is due is not significant.

Costs to Obtain or Fulfill a Customer Contract

Accounts Receivable

Accounts Receivable

Other Current Assets

Other Current Assets

Other current assets consisted of the following as of June 30, 2018 and December 31, 2017:

	June 30, 2018		December 31, 2017
	(unaudited)

Indemnification asset	$	875	$	875
Prepaid assets		556		266
Other		43		31
	$	1,474	$	1,172

Long-Lived Assets, Including Finite-lived Intangible Assets

Long-Lived Assets, including Finite-Lived Intangible Assets

Discontinued Operations

Discontinued Operations

Basic and Diluted Net Loss Per Share

Basic and Diluted Net Loss per Share

A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and six-month periods ended June 30, 2018 and 2017 is as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2018		2017		2018		2017
	(unaudited)

Basic weighted average number of common shares		27,933		9,657		27,894		6,877
Potential dilutive effect of stock-based awards		-		-		-		-
Diluted weighted average number of common shares		27,933		9,657		27,894		6,877

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2018		2017		2018		2017
	(unaudited)

Options		2,256		323		2,256		323
Stock-settled stock appreciation rights (SARs)		59		85		59		85
Restricted stock units (RSUs)		220		68		220		68
Warrants		13,542		17,105		13,542		17,105
		16,077		17,581		16,077		17,581

- Definition

Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5212-111524

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 11B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84173941&loc=SL6953423-111524

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84173941&loc=d3e5093-111524

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(9))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

XML 37 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Schedule of Effect of Adoption of ASC Topic 606 on Condensed Consolidated Balance Sheet and Statement of Operations

The following tables present the effect of the adoption of ASC Topic 606 on our condensed consolidated balance sheet and revenue as of and for the six months ended June 30, 2018:

Consolidated Balance Sheet:

	June 30, 2018
				(unaudited)
	As reported			Balances without Adoption of ASC 606			Effect of Change Higher/(Lower)
Accounts receivable, net	$	7,647		$	6,731		$	916
Accumulated deficit		(134,410	)		(136,910	)		(2,500	)

Revenue:

	For the six months ended June 30, 2018
			(unaudited)
	As reported		Balances without Adoption of ASC 606		Effect of Change Higher/(Lower)
Revenue, net	$	10,310	$	9,580	$	730

Schedule of Other Current Assets

Other current assets consisted of the following as of June 30, 2018 and December 31, 2017:

	June 30, 2018		December 31, 2017
	(unaudited)

Indemnification asset	$	875	$	875
Prepaid assets		556		266
Other		43		31
	$	1,474	$	1,172

Schedule of Weighted Average Number of Shares

A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and six-month periods ended June 30, 2018 and 2017 is as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2018		2017		2018		2017
	(unaudited)

Basic weighted average number of common shares		27,933		9,657		27,894		6,877
Potential dilutive effect of stock-based awards		-		-		-		-
Diluted weighted average number of common shares		27,933		9,657		27,894		6,877

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2018		2017		2018		2017
	(unaudited)

Options		2,256		323		2,256		323
Stock-settled stock appreciation rights (SARs)		59		85		59		85
Restricted stock units (RSUs)		220		68		220		68
Warrants		13,542		17,105		13,542		17,105
		16,077		17,581		16,077		17,581

XML 38 R27.htm IDEA: XBRL DOCUMENT

Other Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Identifiable Intangible Assets Carrying Value

The net carrying value of the identifiable intangible assets as of June 30, 2018 and December 31, 2017 are as follows:

			As of June 30, 2018			As of December 31, 2017
			(unaudited)
	Life		Carrying			Carrying
	(Years)		Amount			Amount
Diagnostic assets:
Asuragen acquisition:
Thyroid		9	$	8,519		$	8,519
RedPath acquisition:
Pancreas test		7		16,141			16,141
Barrett’s test		9		18,351			18,351
Total			$	43,011		$	43,011
Diagnostic lab:
CLIA Lab		2.3	$	609		$	609

Accumulated Amortization			$	(12,140	)	$	(10,515	)

Net Carrying Value			$	31,480		$	33,105

Schedule of Future Estimated Amortization Expense

Amortization of our diagnostic assets begins upon launch of the product. Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:

2018				2019				2020				2021				2022
$	3,252			$	5,292			$	5,292			$	4,908			$	2,987

XML 39 R28.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, are set forth in the tables below:

	As of June 30, 2018				Fair Value Measurements
	Carrying		Fair		As of June 30, 2018
	Amount		Value		Level 1		Level 2		Level 3
	(unaudited)
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	1,427	$	1,427	$	-	$	-	$	1,427
Other long-term liabilities:
Warrant liability ⁽²⁾		407		407		-		-		407
	$	1,834	$	1,834	$	-	$	-	$	1,834

	As of December 31, 2017				Fair Value Measurements
	Carrying		Fair		As of December 31, 2017
	Amount		Value		Level 1		Level 2		Level 3
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	1,581	$	1,581	$	-	$	-	$	1,581
Other long-term liabilities:
Warrant liability ⁽²⁾		473		473		-		-		473
	$	2,054	$	2,054	$	-	$	-	$	2,054

⁽¹⁾⁽²⁾See Note 7, Accrued Expenses and Long-Term Liabilities

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

A roll forward of the carrying value of the Contingent consideration liability and the Underwriters’ Warrant to June 30, 2018 is as follows:

								Cancellation		Mark to
	December 31,							of Obligation/		Market			June 30,
	2017		Payments			Accretion		Conversions		Adjustment			2018
	(unaudited)

Asuragen	$	1,581	$	(155	)	$	1	$	-	$	-		$	1,427

Underwriters Warrant		473		-					-		(66	)		407
	$	2,054	$	(155	)	$	1	$	-	$	(66	)	$	1,834

XML 40 R29.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Long-Term Liabilities (Tables)

6 Months Ended

Jun. 30, 2018

Payables and Accruals [Abstract]

Schedule of Other Accrued Expenses

Other accrued expenses consisted of the following as of June 30, 2018 and December 31, 2017:

	June 30, 2018		December 31, 2017
		(unaudited)

Accrued royalties	$	573	$	296
Indemnification liability		875		875
Contingent consideration		316		232
DOJ settlement		150		500
Accrued professional fees		690		700
Taxes payable		471		515
Unclaimed property		565		565
All others		664		1,321
	$	4,304	$	5,004

Schedule of Long Term Liabilities

Long-term liabilities consisted of the following as of June 30, 2018 and December 31, 2017:

	June 30, 2018		December 31, 2017
	(unaudited)

Warrant liability	$	407	$	473
Uncertain tax positions		3,838		3,734
Other		94		82
	$	4,339	$	4,289

XML 41 R30.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions

The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the six-month periods ended June 30, 2018 and 2017.

	Six Months Ended
	June 30, 2018			June 30, 2017
	(unaudited)

Risk-free interest rate		2.65	%		1.96	%
Expected life		6.00			4.91
Expected volatility		126.93	%		138.71	%
Dividend yield		-			-

XML 42 R31.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

6 Months Ended

Jun. 30, 2018

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate Reconciliation

The following table summarizes income tax expense on (loss) income from continuing operations and the effective tax rate for the three- and six-month periods ended June 30, 2018 and 2017:

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2018			2017			2018			2017
	(unaudited)						(unaudited)

Provision (benefit) from income tax	$	8		$	(301	)	$	14		$	(298	)
Effective income tax rate		(0.4	)%		4.6	%		(0.3	)%		6.4	%

XML 43 R32.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2018

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations Amount Recognized in Balance Sheet

The components of liabilities classified as discontinued operations relate to Commercial Services and consist of the following as of June 30, 2018 and December 31, 2017:

	June 30, 2018		December 31, 2017
	(unaudited)

Accounts payable	$	192	$	192
Other		747		1,110
Current liabilities from discontinued operations		939		1,302
Total liabilities	$	939	$	1,302

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

XML 44 R33.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information (Tables)

6 Months Ended

Jun. 30, 2018

Supplemental Cash Flow Elements [Abstract]

Schedule of Supplemental Disclosure of Cash flow Information

13.

SUPPLEMENTAL CASH FLOW INFORMATION

The following table presents cash flows used in the Company’s discontinued operations for the six months ended June 30, 2018 and 2017:

	Six Months Ended
	June 30,
	2018			2017
	(unaudited)
Net cash used in operating activities of discontinued operations	$	(354	)	$	(883	)

Supplemental Cash Flow Information

(in thousands)

	Six Months Ended
	June 30,
	2018		2017
	(unaudited)
Operating
Adoption of ASC 606	$	2,500	$	-
Prepaid stock grants issued to vendors	$	286	$	-

Investing
Acquisition of property and equipment in other accrued expenses	$	46	$	-

Financing
Settlement of the RedPath Note	$	-	$	(8,098	)
Issuance of the Exchange Notes	$	-	$	11,375
Non-cash equity conversion costs	$	-	$	(173	)
Debt issuance costs	$	-	$	(511	)
Warrants issued through Termination Agreement*	$	-	$	193
Common shares issued in debt exchange	$	-	$	8,869

*See Note 14, Equity

XML 45 R34.htm IDEA: XBRL DOCUMENT

Warrants (Tables)

6 Months Ended

Jun. 30, 2018

Warrants

Schedule of Warrants Outstanding and Warrants Activity

Warrants outstanding for the period ended June 30, 2018 are as follows:

Description	Classification	Exercise Price		Expiration Date	Warrants Issued		Warrants Exercised			Warrants Cancelled/ Expired			Balance December 31, 2017		Balance June 30, 2018

Private Placement Warrants, issued January 25, 2017	Equity	$	4.69	June 2022		855,000		-			-			855,000		855,000
RedPath Warrants, issued March 22, 2017	Equity	$	4.69	September 2022		100,000		-			-			100,000		100,000
Pre-Funded Warrants, issued June 21, 2017	Liability	$	0.01	None		2,600,000		(2,600,000	)		-			-		-
Underwriters Warrants, issued June 21, 2017	Liability	$	1.32	December 2022		575,000		-			(40,000	)		535,000		535,000
Base & Overallotment Warrants, issued June 21, 2017	Equity	$	1.25	June 2022		14,375,000		(5,672,852	)		-			8,702,148		8,702,148
Vendor Warrants, issued August 6, 2017	Equity	$	1.25	August 2020		150,000		-			-			150,000		150,000
Warrants issued October 12, 2017	Equity	$	1.80	April 2022		3,200,000		-			-			3,200,000		3,200,000

						21,855,000		(8,272,852	)		(40,000	)		13,542,148		13,542,148

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 46 R35.htm IDEA: XBRL DOCUMENT

Liquidity (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Liquidity (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 10,084	$ 14,265	$ 10,084	$ 14,265	$ 15,199	$ 602
Accounts receivable, net	7,647		7,647		3,437
Total current assets	19,205		19,205		19,808
Total current liabilities	7,354		7,354		$ 8,091
Net loss	$ 1,917	$ 6,306	5,110	3,892
Net cash used in operating activities			$ 5,027	$ 8,572

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 47 R36.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($) Integer	Jun. 30, 2017 USD ($)
Accounts receivable related to the adjustment	$ 1,710	$ 512
Number of operating segment \| Integer	1
Minimum [Member]
Finite-lived intangible asset, useful life	2 years
Maximum [Member]
Finite-lived intangible asset, useful life	9 years
Adoption of ASC Topic 606 [Member]
Cumulative adjustment to opening accumulated deficit and increase of accounts receivable	$ 2,500
Accounts receivable related to the adjustment	$ 900

XML 48 R37.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Effect of Adoption of ASC Topic 606 on Condensed Consolidated Balance Sheet and Statement of Operations (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Accounts receivable, net	$ 7,647	$ 3,437
Accumulated deficit	(134,410)	$ (131,800)
Revenue, net	10,310
Balances without Adoption of ASC 606 [Member]
Accounts receivable, net	6,731
Accumulated deficit	(136,910)
Revenue, net	9,580
Effect of Change Higher/(Lower) [Member]
Accounts receivable, net	916
Accumulated deficit	(2,500)
Revenue, net	$ 730

XML 49 R38.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Indemnification assets	$ 875	$ 875
Prepaid assets	556	266
Other	43	31
Other current assets	$ 1,474	$ 1,172

XML 50 R39.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Weighted Average Number of Shares (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Accounting Policies [Abstract]
Basic weighted average number of common shares	27,933,000	9,657,000	27,894,000	6,877,000
Potential dilutive effect of stock-based awards
Diluted weighted average number of common shares	27,933,000	9,657,000	27,894,000	6,877,000

XML 51 R40.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share	16,077,000	17,581,000	16,077,000	17,851,000
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	2,256,000	323,000	2,256,000	323,000
Stock-Settled Stock Appreciation Rights (SARs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	59,000	85,000	59,000	85,000
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	220,000	68,000	220,000	68,000
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share	13,542,000	17,105,000	13,542,000	17,105,000

XML 52 R41.htm IDEA: XBRL DOCUMENT

Other Intangible Assets (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 813	$ 813	$ 1,626	$ 1,626

XML 53 R42.htm IDEA: XBRL DOCUMENT

Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Finite-lived Intangible Assets, Accumulated Amortization	$ (12,140)	$ (10,515)
Finite-lived Intangible Assets, Net Carrying Value	$ 31,480	33,105
Diagnostic Assets, Thyroid [Member] \| Asuragen Acquisition [Member]
Finite-lived Intangible Asset, Useful Life (Years)	9 years
Finite-lived Intangible Assets, Gross	$ 8,519	8,519
Diagnostic Assets, Pancreas Test [Member] \| RedPath Acquisition [Member]
Finite-lived Intangible Asset, Useful Life (Years)	7 years
Finite-lived Intangible Assets, Gross	$ 16,141	16,141
Diagnostic Assets, Barrett's Test [Member] \| RedPath Acquisition [Member]
Finite-lived Intangible Asset, Useful Life (Years)	9 years
Finite-lived Intangible Assets, Gross	$ 18,351		$ 18,351
Diagnostic Lab, CLIA Lab [Member]
Finite-lived Intangible Asset, Useful Life (Years)	2 years 3 months 19 days
Finite-lived Intangible Assets, Gross	$ 609	609
Diagnostic Assets [Member]
Finite-lived Intangible Assets, Gross	$ 43,011	$ 43,011

XML 54 R43.htm IDEA: XBRL DOCUMENT

Other Intangible Assets - Schedule of Future Estimated Amortization Expense (Details) $ in Thousands	Jun. 30, 2018 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2018	$ 3,252
2019	5,292
2020	5,292
2021	4,908
2022	$ 2,987

XML 55 R44.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details Narrative)	Jun. 21, 2017 shares
Pre-Funded Warrants [Member]
Warrant to purchase shares of common stock	2,600,000
Underwriter Warrants[Member]
Warrant to purchase shares of common stock	575,000

XML 56 R45.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Financial Instrument Measured on Recurring Basis (Details) - USD ($)
$ in Thousands

Jun. 30, 2018

Dec. 31, 2017

Reported Value Measurement [Member]

Warrant liability

^[1]

$ 407

$ 473

Fair value of liabilities

1,834

2,054

Fair Value Measurements [Member]

Warrant liability

^[1]

407

473

Fair value of liabilities

1,834

2,054

Level 1 [Member]

Warrant liability

^[1]

Fair value of liabilities

Level 2 [Member]

Warrant liability

^[1]

Fair value of liabilities

Level 3 [Member]

Warrant liability

^[1]

407

473

Fair value of liabilities

1,834

2,054

Asuragen [Member]

Contingent consideration

^[1]

1,427

1,581

Asuragen [Member] | Fair Value Measurements [Member]

Contingent consideration

^[1]

1,427

1,581

Asuragen [Member] | Level 1 [Member]

Contingent consideration

^[1]

Asuragen [Member] | Level 2 [Member]

Contingent consideration

^[1]

Asuragen [Member] | Level 3 [Member]

Contingent consideration

^[1]

$ 1,427

$ 1,581

[1]	See Note 7, Accrued Expenses and Long-Term Liabilities

XML 57 R46.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($)
Beginning Balance	$ 2,054
Payments	(155)
Accretion	1
Cancellation of Obligation/Conversions
Mark to Market Adjustment	(66)
Ending Balance	1,834
Underwriter Warrants [Member]
Beginning Balance	473
Payments
Accretion
Cancellation of Obligation/Conversions
Mark to Market Adjustment	(66)
Ending Balance	407
Asuragen [Member]
Beginning Balance	1,581
Payments	(155)
Accretion	1
Cancellation of Obligation/Conversions
Mark to Market Adjustment
Ending Balance	$ 1,427

XML 58 R47.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative)			6 Months Ended		12 Months Ended	36 Months Ended
Commitments and Contingencies (Details Narrative)	Mar. 15, 2018 USD ($) ft²	Mar. 09, 2017 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 USD ($)
Promissory note				$ 11,375,000
Pittsburgh Lease [Member]
Operating lease expire date description	Extend it through June 30, 2023
Number of square foot for laboratory and office space \| ft²	20,000
Operating lease, description	The lease is for 20,000 square feet of laboratory and office space, with monthly base rent of $33,333 beginning July 1, 2018, escalating by twenty-five percent (25%) on July 1, 2019 to $41,667 per month. The Company may, at its option, extend the term of the Lease for two consecutive terms of five years each, with the monthly based rent escalating by ten percent (10%) for each of the additional five year terms.
Pittsburgh Lease [Member] \| July 1, 2018 [Member]
Monthly base rent	$ 33,333
Pittsburgh Lease [Member] \| July 1, 2019 [Member]
Monthly base rent	$ 41,667
Companys Counter-Claim Against Prolias [Member]
Litigation settlement, amount		$ 500,000
Loss contingency, damages sought, value		636,053
Promissory note		$ 1,000,000
Settlement Agreement [Member] \| RedPath [Member]
Payments for legal settlements			$ 150,000		$ 500,000
Loss contingency accrual, payments					$ 500,000
Settlement Agreement [Member] \| RedPath [Member] \| Maximum [Member]
Litigation settlement, amount						$ 3,000,000

XML 59 R48.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Long-Term Liabilities - Schedule of Other Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued royalties	$ 573	$ 296
Indemnification liability	875	875
Contingent consideration	316	232
DOJ settlement	150	500
Accrued professional fees	690	700
Taxes payable	471	515
Unclaimed property	565	565
All others	664	1,321
Total other accrued expenses	$ 4,304	$ 5,004

XML 60 R49.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Long-Term Liabilities - Schedule of Long Term Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Warrant liability	$ 407	$ 473
Uncertain tax positions	3,838	3,734
Other	94	82
Long-term liabilities	$ 4,339	$ 4,289

XML 61 R50.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based compensation expense	$ 400		$ 100	$ 1,016	$ 206
Stock Incentive Plan [Member]
Share-based compensation arrangement by share-based payment award, description				Stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for employees and members of the Board of Directors. Upon exercise, new shares will be issued by the Company. The Company granted stock options in 2018 and 2017 which vest monthly over a one-year period. SARs are generally granted with a grant price equal to the market value of the common stock on the date of grant, vest one-third each year on the anniversary of the date of grant and expire five years from the date of grant. The restricted shares and restricted stock units granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.
Share-based compensation arrangement, options, grants in period, gross		745,600
Share-based compensation arrangements, options, grants in period, weighted average exercise price		$ 1.01
Stock Incentive Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based compensation arrangement, options, grants in period, gross		186,400
Share-based compensation arrangement, award vesting period		3 years

XML 62 R51.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate	2.65%	1.96%
Expected life	6 years	4 years 10 months 28 days
Expected volatility	126.93%	138.71%
Dividend yield	0.00%	0.00%

XML 63 R52.htm IDEA: XBRL DOCUMENT

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Provision (benefit) from income tax	$ 8	$ (301)	$ 14	$ (298)
Effective income tax rate	(0.40%)	4.60%	(0.30%)	6.40%

XML 64 R53.htm IDEA: XBRL DOCUMENT

Segment Information (Details Narrative)	Dec. 22, 2015 Integer
Segment Reporting [Abstract]
Number of reportable segments	1

XML 65 R54.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Schedule of Discontinued Operations Amount Recognized in Balance Sheet (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Accounts payable	$ 192	$ 192
Other	747	1,110
Current liabilities from discontinued operations	939	1,302
Total liabilities	$ 939	$ 1,302

XML 66 R55.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
Long-Term Debt (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Extinguishment fair value loss		$ (2,731)		$ (4,278)
Exchange Agreement [Member] \| Senior Convertible Notes [Member] \| March 23, 2017 and April 18, 2017 [Member]
Debt conversion, converted instrument, shares issued			3,795,429
Extinguishment fair value loss					$ 4,300

XML 67 R56.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information - Schedule of Supplemental Disclosure of Cash flow Information (Details) - USD ($)
$ in Thousands

6 Months Ended

Jun. 30, 2018

Jun. 30, 2017

Supplemental Cash Flow Elements [Abstract]

Net cash used in operating activities of discontinued operations

$ (354)

$ (883)

Adoption of ASC 606

2,500

Prepaid stock grants issued to vendors

286

Acquisition of property and equipment in other accrued expenses

Settlement of the RedPath Note

(8,098)

Issuance of the Exchange Notes

11,375

Non-cash equity conversion costs

(173)

Debt issuance costs

(511)

Warrants issued through Termination Agreement

^[1]

193

Common shares issued in debt exchange

$ 8,869

[1]	See Note 14, Equity

XML 68 R57.htm IDEA: XBRL DOCUMENT

Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2017	Jun. 30, 2017	Jun. 30, 2018
Number of common stock issued, shares	2,793,000	9,900,000
Warrants to purchase shares of common stock	855,000
Gross proceeds from equity offerings	$ 12,200
Warrants exercise price description		Each Firm Share and accompanying Base Warrant was sold for a combined effective price of $1.10, and each Pre-Funded Warrant and accompanying Base Warrant was sold for a combined effective price of $1.09.
Gross proceeds from warrants		$ 13,700
Net proceeds from warrants		$ 12,300
Base Warrants [Member]
Warrants to purchase shares of common stock		12,500,000
Warrant exercise price		$ 1.25
Pre-Funded Warrants [Member]
Warrants to purchase shares of common stock		2,600,000
Warrant exercise price		$ 0.01	$ 0.01
Termination Agreement [Member] \| RedPath Equityholder Representative, LLC [Member]
Warrants to purchase shares of common stock	100,000
Warrant term	5 years
Common stock price, per share	$ 4.69
RedPath Debt Exchange and conversion of Senior Convertible Notes [Member]
Number of common stock issued, shares	3,795,429

XML 69 R58.htm IDEA: XBRL DOCUMENT

Warrants - Schedule of Warrants Outstanding and Warrants Activity (Details) - $ / shares	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017
Warrants Issued	21,855,000
Warrants Exercised	(8,272,852)
Warrants Cancelled/Expired	(40,000)
Warrants	13,542,148	13,542,148
Private Placement Warrants[Member]
Description	Private Placement Warrants, issued January 25, 2017
Classification	Equity
Exercise Price	$ 4.69
Expiration Date	June 2022
Warrants Issued	855,000
Warrants Exercised
Warrants Cancelled/Expired
Warrants	855,000	855,000
RedPath Warrants[Member]
Description	RedPath Warrants, issued March 22, 2017
Classification	Equity
Exercise Price	$ 4.69
Expiration Date	September 2022
Warrants Issued	100,000
Warrants Exercised
Warrants Cancelled/Expired
Warrants	100,000	100,000
Pre-Funded Warrants [Member]
Description	Pre-Funded Warrants, issued June 21, 2017
Classification	Liability
Exercise Price	$ 0.01		$ 0.01
Expiration Date	None
Warrants Issued	2,600,000
Warrants Exercised	(2,600,000)
Warrants Cancelled/Expired
Warrants
Underwriter Warrants [Member]
Description	Underwriters Warrants, issued June 21, 2017
Classification	Liability
Exercise Price	$ 1.32
Expiration Date	December 2022
Warrants Issued	575,000
Warrants Exercised
Warrants Cancelled/Expired	(40,000)
Warrants	535,000	535,000
Base & Overallotment Warrants [Member]
Description	Base & Overallotment Warrants, issued June 21, 2017
Classification	Equity
Exercise Price	$ 1.25
Expiration Date	June 2022
Warrants Issued	14,375,000
Warrants Exercised	(5,672,852)
Warrants Cancelled/Expired
Warrants	8,702,148	8,702,148
Vendor Warrants [Member]
Description	Vendor Warrants, issued August 6, 2017
Classification	Equity
Exercise Price	$ 1.25
Expiration Date	August 2020
Warrants Issued	150,000
Warrants Exercised
Warrants Cancelled/Expired
Warrants	150,000	150,000
Warrants Issued [Member]
Description	Warrants issued october 12 2017
Classification	Equity
Exercise Price	$ 1.80
Expiration Date	April 2022
Warrants Issued	3,200,000
Warrants Exercised
Warrants Cancelled/Expired
Warrants	3,200,000	3,200,000

XML 70 R59.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - Subsequent Event [Member] $ in Thousands	1 Months Ended
	Jul. 31, 2018 USD ($)
Line of credit, term	3 years
Line of credit	$ 4,000
Line of credit net available receivables	80.00%
Expansion capital	$ 850

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 72 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 125 228 1 true 50 0 false 6 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://interpacediagnostics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://interpacediagnostics.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://interpacediagnostics.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://interpacediagnostics.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Sheet http://interpacediagnostics.com/role/StatementsOfOperationsParenthetical Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Stockholder's Equity (Unaudited) Sheet http://interpacediagnostics.com/role/StatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholder's Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://interpacediagnostics.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Basis of Presentation Sheet http://interpacediagnostics.com/role/BasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 00000009 - Disclosure - Liquidity Sheet http://interpacediagnostics.com/role/Liquidity Liquidity Notes 9 false false R10.htm 00000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://interpacediagnostics.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 00000011 - Disclosure - Other Intangible Assets Sheet http://interpacediagnostics.com/role/OtherIntangibleAssets Other Intangible Assets Notes 11 false false R12.htm 00000012 - Disclosure - Fair Value Measurements Sheet http://interpacediagnostics.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 00000013 - Disclosure - Commitments and Contingencies Sheet http://interpacediagnostics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 00000014 - Disclosure - Accrued Expenses and Long-Term Liabilities Sheet http://interpacediagnostics.com/role/AccruedExpensesAndLong-termLiabilities Accrued Expenses and Long-Term Liabilities Notes 14 false false R15.htm 00000015 - Disclosure - Stock-Based Compensation Sheet http://interpacediagnostics.com/role/Stock-basedCompensation Stock-Based Compensation Notes 15 false false R16.htm 00000016 - Disclosure - Income Taxes Sheet http://interpacediagnostics.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 00000017 - Disclosure - Segment Information Sheet http://interpacediagnostics.com/role/SegmentInformation Segment Information Notes 17 false false R18.htm 00000018 - Disclosure - Discontinued Operations Sheet http://interpacediagnostics.com/role/DiscontinuedOperations Discontinued Operations Notes 18 false false R19.htm 00000019 - Disclosure - Long-Term Debt Sheet http://interpacediagnostics.com/role/Long-termDebt Long-Term Debt Notes 19 false false R20.htm 00000020 - Disclosure - Supplemental Cash Flow Information Sheet http://interpacediagnostics.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 20 false false R21.htm 00000021 - Disclosure - Equity Sheet http://interpacediagnostics.com/role/Equity Equity Notes 21 false false R22.htm 00000022 - Disclosure - Warrants Sheet http://interpacediagnostics.com/role/Warrants Warrants Notes 22 false false R23.htm 00000023 - Disclosure - Recent Accounting Pronouncements Sheet http://interpacediagnostics.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 23 false false R24.htm 00000024 - Disclosure - Subsequent Events Sheet http://interpacediagnostics.com/role/SubsequentEvents Subsequent Events Notes 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://interpacediagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://interpacediagnostics.com/role/SummaryOfSignificantAccountingPolicies 25 false false R26.htm 00000026 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://interpacediagnostics.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://interpacediagnostics.com/role/SummaryOfSignificantAccountingPolicies 26 false false R27.htm 00000027 - Disclosure - Other Intangible Assets (Tables) Sheet http://interpacediagnostics.com/role/OtherIntangibleAssetsTables Other Intangible Assets (Tables) Tables http://interpacediagnostics.com/role/OtherIntangibleAssets 27 false false R28.htm 00000028 - Disclosure - Fair Value Measurements (Tables) Sheet http://interpacediagnostics.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://interpacediagnostics.com/role/FairValueMeasurements 28 false false R29.htm 00000029 - Disclosure - Accrued Expenses and Long-Term Liabilities (Tables) Sheet http://interpacediagnostics.com/role/AccruedExpensesAndLong-termLiabilitiesTables Accrued Expenses and Long-Term Liabilities (Tables) Tables http://interpacediagnostics.com/role/AccruedExpensesAndLong-termLiabilities 29 false false R30.htm 00000030 - Disclosure - Stock-Based Compensation (Tables) Sheet http://interpacediagnostics.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://interpacediagnostics.com/role/Stock-basedCompensation 30 false false R31.htm 00000031 - Disclosure - Income Taxes (Tables) Sheet http://interpacediagnostics.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://interpacediagnostics.com/role/IncomeTaxes 31 false false R32.htm 00000032 - Disclosure - Discontinued Operations (Tables) Sheet http://interpacediagnostics.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://interpacediagnostics.com/role/DiscontinuedOperations 32 false false R33.htm 00000033 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://interpacediagnostics.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://interpacediagnostics.com/role/SupplementalCashFlowInformation 33 false false R34.htm 00000034 - Disclosure - Warrants (Tables) Sheet http://interpacediagnostics.com/role/WarrantsTables Warrants (Tables) Tables http://interpacediagnostics.com/role/Warrants 34 false false R35.htm 00000035 - Disclosure - Liquidity (Details Narrative) Sheet http://interpacediagnostics.com/role/LiquidityDetailsNarrative Liquidity (Details Narrative) Details http://interpacediagnostics.com/role/Liquidity 35 false false R36.htm 00000036 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://interpacediagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://interpacediagnostics.com/role/SummaryOfSignificantAccountingPoliciesTables 36 false false R37.htm 00000037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Effect of Adoption of ASC Topic 606 on Condensed Consolidated Balance Sheet and Statement of Operations (Details) Sheet http://interpacediagnostics.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfEffectOfAdoptionOfAscTopic606OnCondensedConsolidatedBalanceSheetAndStatementOfOperationsDetails Summary of Significant Accounting Policies - Schedule of Effect of Adoption of ASC Topic 606 on Condensed Consolidated Balance Sheet and Statement of Operations (Details) Details 37 false false R38.htm 00000038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Other Current Assets (Details) Sheet http://interpacediagnostics.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfOtherCurrentAssetsDetails Summary of Significant Accounting Policies - Schedule of Other Current Assets (Details) Details 38 false false R39.htm 00000039 - Disclosure - Summary of Significant Accounting Policies - Schedule of Weighted Average Number of Shares (Details) Sheet http://interpacediagnostics.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfWeightedAverageNumberOfSharesDetails Summary of Significant Accounting Policies - Schedule of Weighted Average Number of Shares (Details) Details 39 false false R40.htm 00000040 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://interpacediagnostics.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 40 false false R41.htm 00000041 - Disclosure - Other Intangible Assets (Details Narrative) Sheet http://interpacediagnostics.com/role/OtherIntangibleAssetsDetailsNarrative Other Intangible Assets (Details Narrative) Details http://interpacediagnostics.com/role/OtherIntangibleAssetsTables 41 false false R42.htm 00000042 - Disclosure - Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details) Sheet http://interpacediagnostics.com/role/OtherIntangibleAssets-ScheduleOfIdentifiableIntangibleAssetsCarryingValueDetails Other Intangible Assets - Schedule of Identifiable Intangible Assets Carrying Value (Details) Details 42 false false R43.htm 00000043 - Disclosure - Other Intangible Assets - Schedule of Future Estimated Amortization Expense (Details) Sheet http://interpacediagnostics.com/role/OtherIntangibleAssets-ScheduleOfFutureEstimatedAmortizationExpenseDetails Other Intangible Assets - Schedule of Future Estimated Amortization Expense (Details) Details 43 false false R44.htm 00000044 - Disclosure - Fair Value Measurements (Details Narrative) Sheet http://interpacediagnostics.com/role/FairValueMeasurementsDetailsNarrative Fair Value Measurements (Details Narrative) Details http://interpacediagnostics.com/role/FairValueMeasurementsTables 44 false false R45.htm 00000045 - Disclosure - Fair Value Measurements - Schedule of Financial Instrument Measured on Recurring Basis (Details) Sheet http://interpacediagnostics.com/role/FairValueMeasurements-ScheduleOfFinancialInstrumentMeasuredOnRecurringBasisDetails Fair Value Measurements - Schedule of Financial Instrument Measured on Recurring Basis (Details) Details 45 false false R46.htm 00000046 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) Sheet http://interpacediagnostics.com/role/FairValueMeasurements-ScheduleOfFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationDetails Fair Value Measurements - Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) Details 46 false false R47.htm 00000047 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://interpacediagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://interpacediagnostics.com/role/CommitmentsAndContingencies 47 false false R48.htm 00000048 - Disclosure - Accrued Expenses and Long-Term Liabilities - Schedule of Other Accrued Expenses (Details) Sheet http://interpacediagnostics.com/role/AccruedExpensesAndLong-termLiabilities-ScheduleOfOtherAccruedExpensesDetails Accrued Expenses and Long-Term Liabilities - Schedule of Other Accrued Expenses (Details) Details 48 false false R49.htm 00000049 - Disclosure - Accrued Expenses and Long-Term Liabilities - Schedule of Long Term Liabilities (Details) Sheet http://interpacediagnostics.com/role/AccruedExpensesAndLong-termLiabilities-ScheduleOfLongTermLiabilitiesDetails Accrued Expenses and Long-Term Liabilities - Schedule of Long Term Liabilities (Details) Details 49 false false R50.htm 00000050 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://interpacediagnostics.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://interpacediagnostics.com/role/Stock-basedCompensationTables 50 false false R51.htm 00000051 - Disclosure - Stock-Based Compensation - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details) Sheet http://interpacediagnostics.com/role/Stock-basedCompensation-ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails Stock-Based Compensation - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details) Details 51 false false R52.htm 00000052 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://interpacediagnostics.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) Details 52 false false R53.htm 00000053 - Disclosure - Segment Information (Details Narrative) Sheet http://interpacediagnostics.com/role/SegmentInformationDetailsNarrative Segment Information (Details Narrative) Details http://interpacediagnostics.com/role/SegmentInformation 53 false false R54.htm 00000054 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations Amount Recognized in Balance Sheet (Details) Sheet http://interpacediagnostics.com/role/DiscontinuedOperations-ScheduleOfDiscontinuedOperationsAmountRecognizedInBalanceSheetDetails Discontinued Operations - Schedule of Discontinued Operations Amount Recognized in Balance Sheet (Details) Details 54 false false R55.htm 00000055 - Disclosure - Long-Term Debt (Details Narrative) Sheet http://interpacediagnostics.com/role/Long-termDebtDetailsNarrative Long-Term Debt (Details Narrative) Details http://interpacediagnostics.com/role/Long-termDebt 55 false false R56.htm 00000056 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Disclosure of Cash flow Information (Details) Sheet http://interpacediagnostics.com/role/SupplementalCashFlowInformation-ScheduleOfSupplementalDisclosureOfCashFlowInformationDetails Supplemental Cash Flow Information - Schedule of Supplemental Disclosure of Cash flow Information (Details) Details 56 false false R57.htm 00000057 - Disclosure - Equity (Details Narrative) Sheet http://interpacediagnostics.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://interpacediagnostics.com/role/Equity 57 false false R58.htm 00000058 - Disclosure - Warrants - Schedule of Warrants Outstanding and Warrants Activity (Details) Sheet http://interpacediagnostics.com/role/Warrants-ScheduleOfWarrantsOutstandingAndWarrantsActivityDetails Warrants - Schedule of Warrants Outstanding and Warrants Activity (Details) Details 58 false false R59.htm 00000059 - Disclosure - Subsequent Events (Details Narrative) Sheet http://interpacediagnostics.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://interpacediagnostics.com/role/SubsequentEvents 59 false false All Reports Book All Reports idxg-20180630.xml idxg-20180630.xsd idxg-20180630_cal.xml idxg-20180630_def.xml idxg-20180630_lab.xml idxg-20180630_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 77 0001493152-18-011292-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-011292-xbrl.zip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end